CHEBI ONTOLOGY - ANNOTATIONS |
|
The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
|
Term: | hydralazine |
|
Accession: | CHEBI:5775
|
browse the term
|
Definition: | The 1-hydrazino derivative of phthalazine; a direct-acting vasodilator that is used as an antihypertensive agent. |
Synonyms: | related_synonym: | (1Z)-1(2H)-Phthalazinone hydrazone; (2H)-Phthalazinone hydrazone; 1-Hydrazinophthalazine; 1-Phthalazinylhydrazine; 6-Hydralazine; Formula=C8H8N4; Hydralazin; Hydrallazine; Hydrazinophthalazine; Hydrazone 1(2H)-phthalazinone; Hypophthalin; Idralazina; InChI=1S/C8H8N4/c9-11-8-7-4-2-1-3-6(7)5-10-12-8/h1-5H,9H2,(H,11,12); InChIKey=RPTUSVTUFVMDQK-UHFFFAOYSA-N; SMILES=NNc1nncc2ccccc12; hidralazina; hydralazinum; phthalazin-1-ylhydrazine |
| xref: | Beilstein:132615; CAS:86-54-4; DrugBank:DB01275; Drug_Central:1384; Gmelin:4337; KEGG:C07040; KEGG:D08044; LINCS:LSM-15370 |
| xref_mesh: | MESH:D006830 |
| xref: | PMID:808562; Patent:US2484029; Wikipedia:Hydralazine |
|
|
|
G |
Abcb5 |
ATP binding cassette subfamily B member 5 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in decreased expression of ABCB5 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 6:139,836,528...139,932,830
Ensembl chr 6:139,835,949...139,932,830
|
|
G |
Acaa1a |
acetyl-CoA acyltransferase 1A |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of ACAA1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 8:119,079,401...119,088,626
Ensembl chr 8:119,079,775...119,088,624
|
|
G |
Acad9 |
acyl-CoA dehydrogenase family, member 9 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of ACAD9 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 2:118,943,170...118,966,150
Ensembl chr 2:118,943,174...118,966,547
|
|
G |
Acat2 |
acetyl-CoA acetyltransferase 2 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of ACAT2 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 1:47,695,833...47,713,879
Ensembl chr 1:47,695,788...47,752,821
|
|
G |
Ace |
angiotensin I converting enzyme |
multiple interactions |
EXP |
Hydralazine inhibits the reaction [Nitric Oxide deficiency results in increased expression of ACE mRNA] |
CTD |
PMID:16326922 |
|
NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131
|
|
G |
Acin1 |
apoptotic chromatin condensation inducer 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of ACIN1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr15:28,102,112...28,147,001
Ensembl chr15:28,102,112...28,147,001
|
|
G |
Acot2 |
acyl-CoA thioesterase 2 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in decreased expression of ACOT2 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 6:103,611,738...103,619,404
Ensembl chr 6:103,611,544...103,619,245
|
|
G |
Acta1 |
actin, alpha 1, skeletal muscle |
multiple interactions |
EXP |
Hydralazine inhibits the reaction [Nitric Oxide deficiency results in increased expression of ACTA1 mRNA] |
CTD |
PMID:16326922 |
|
NCBI chr19:51,883,709...51,886,735
Ensembl chr19:51,883,715...51,886,742
|
|
G |
Adamts10 |
ADAM metallopeptidase with thrombospondin type 1 motif, 10 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of ADAMTS10 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 7:14,331,659...14,361,620
Ensembl chr 7:14,331,745...14,361,620
|
|
G |
Adgra3 |
adhesion G protein-coupled receptor A3 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of ADGRA3 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr14:60,874,719...60,976,341
Ensembl chr14:60,874,715...60,976,332
|
|
G |
Adipor1 |
adiponectin receptor 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of ADIPOR1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr13:45,859,461...45,879,248
Ensembl chr13:45,859,533...45,879,241
|
|
G |
Adsl |
adenylosuccinate lyase |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of ADSL mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 7:112,479,256...112,503,439
Ensembl chr 7:112,479,271...112,503,760
|
|
G |
Afg3l2 |
AFG3 like matrix AAA peptidase subunit 2 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of AFG3L2 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr18:60,954,268...60,999,110
Ensembl chr18:60,954,268...60,999,110
|
|
G |
Agk |
acylglycerol kinase |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of AGK mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 4:69,114,850...69,193,989
Ensembl chr 4:69,114,269...69,193,934
|
|
G |
Agpat2 |
1-acylglycerol-3-phosphate O-acyltransferase 2 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in decreased expression of AGPAT2 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 3:9,416,837...9,428,567
Ensembl chr 3:9,416,843...9,428,371
|
|
G |
Agt |
angiotensinogen |
multiple interactions decreases response to substance |
EXP ISO |
Hydralazine affects the reaction [AGT protein results in increased abundance of Fatty Acids, Nonesterified]; Hydralazine affects the reaction [AGT protein results in increased abundance of Triglycerides]; Hydralazine inhibits the reaction [AGT protein affects the abundance of Cholesterol]; Hydralazine inhibits the reaction [AGT protein modified form results in increased phosphorylation of MAPK1 protein]; Hydralazine inhibits the reaction [AGT protein modified form results in increased phosphorylation of MAPK3 protein]; Hydralazine inhibits the reaction [AGT protein results in decreased expression of CPT1A mRNA] Hydralazine results in decreased susceptibility to AGT protein modified form |
CTD |
PMID:16344371 PMID:19109942 PMID:21289285 |
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Akr1a1 |
aldo-keto reductase family 1 member A1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of AKR1A1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 5:130,092,945...130,130,277
Ensembl chr 5:130,092,732...130,113,674
|
|
G |
Akr1c2 |
aldo-keto reductase family 1, member C2 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of AKR1C2 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr17:65,759,778...65,808,013
Ensembl chr17:65,759,788...65,775,764
|
|
G |
Akt2 |
AKT serine/threonine kinase 2 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of AKT2 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 1:82,877,228...82,933,828
Ensembl chr 1:82,883,547...82,933,817
|
|
G |
Alb |
albumin |
multiple interactions affects binding |
ISO |
Hydralazine inhibits the reaction [[Acrolein binds to ALB protein] which results in increased expression of HMOX1 mRNA] Hydralazine binds to [Acrolein binds to ALB protein] |
CTD |
PMID:32530271 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Aldh18a1 |
aldehyde dehydrogenase 18 family, member A1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of ALDH18A1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 1:239,375,657...239,407,956
Ensembl chr 1:239,375,669...239,407,890
|
|
G |
Aldh9a1 |
aldehyde dehydrogenase 9 family, member A1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of ALDH9A1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr13:79,505,738...79,522,539
Ensembl chr13:79,505,695...79,540,568
|
|
G |
Alox15 |
arachidonate 15-lipoxygenase |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in decreased expression of ALOX15 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr10:55,060,169...55,068,885
Ensembl chr10:55,060,412...55,068,874
|
|
G |
Anapc11 |
anaphase promoting complex subunit 11 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of ANAPC11 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr10:105,875,209...105,886,307
|
|
G |
Andpro |
androgen regulated protein |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of CST4 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 3:136,718,601...136,725,131
Ensembl chr 3:136,718,602...136,724,966
|
|
G |
Ankfn1 |
ankyrin-repeat and fibronectin type III domain containing 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of ANKFN1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr10:74,214,143...74,602,825
Ensembl chr10:74,218,915...74,663,295
|
|
G |
Ankhd1 |
ankyrin repeat and KH domain containing 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of ANKHD1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr18:28,161,882...28,260,917
Ensembl chr18:28,162,311...28,268,024
|
|
G |
Ankib1 |
ankyrin repeat and IBR domain containing 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of ANKIB1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 4:30,333,678...30,457,781
Ensembl chr 4:30,333,677...30,457,781
|
|
G |
Ankrd44 |
ankyrin repeat domain 44 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of ANKRD44 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 9:56,126,746...56,427,661
Ensembl chr 9:56,126,747...56,427,508
|
|
G |
Anxa2 |
annexin A2 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of ANXA2 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 8:70,105,268...70,141,663
Ensembl chr 8:70,105,253...70,141,658
|
|
G |
Aoah |
acyloxyacyl hydrolase |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in decreased expression of AOAH mRNA |
CTD |
PMID:17183730 |
|
NCBI chr17:43,808,110...44,049,458
Ensembl chr17:43,809,638...44,049,148
|
|
G |
Aoc1 |
amine oxidase, copper containing 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of AOC1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 4:77,812,260...77,831,846
Ensembl chr 4:77,812,260...77,831,840
|
|
G |
Apc |
APC regulator of WNT signaling pathway |
decreases methylation |
ISO |
Hydralazine results in decreased methylation of APC promoter |
CTD |
PMID:15862127 |
|
NCBI chr18:25,828,558...25,925,511
Ensembl chr18:25,864,222...25,922,696
|
|
G |
Apcdd1l |
APC down-regulated 1 like |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of APCDD1L mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 3:162,587,484...162,658,362
Ensembl chr 3:162,582,252...162,658,073
|
|
G |
Aqp10 |
aquaporin 10 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of AQP10 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 2:175,402,609...175,407,677
Ensembl chr 2:175,403,263...175,406,815
|
|
G |
Arcn1 |
archain 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of ARCN1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 8:45,057,617...45,082,224
Ensembl chr 8:45,057,619...45,082,247
|
|
G |
Arf1 |
ARF GTPase 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of ARF1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr10:43,997,983...44,014,461
Ensembl chr10:43,997,986...44,014,434
|
|
G |
Arhgap23 |
Rho GTPase activating protein 23 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of ARHGAP23 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr10:82,437,578...82,496,846
Ensembl chr10:82,394,648...82,496,504
|
|
G |
Arhgap40 |
Rho GTPase activating protein 40 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of ARHGAP40 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 3:147,165,781...147,206,552
Ensembl chr 3:147,165,729...147,207,203
|
|
G |
Arhgap5 |
Rho GTPase activating protein 5 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of ARHGAP5 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 6:69,975,904...70,039,299
Ensembl chr 6:69,976,214...70,037,660
|
|
G |
Arhgef12 |
Rho guanine nucleotide exchange factor 12 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of ARHGEF12 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 8:43,350,070...43,475,404
Ensembl chr 8:43,353,799...43,476,366
|
|
G |
Arih2 |
ariadne RBR E3 ubiquitin protein ligase 2 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of ARIH2 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 8:109,296,738...109,355,909
Ensembl chr 8:109,296,738...109,355,852
|
|
G |
Arl2 |
ARF like GTPase 2 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of ARL2 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 1:203,434,129...203,446,156
Ensembl chr 1:203,434,129...203,446,119
|
|
G |
Arl6ip5 |
ARF like GTPase 6 interacting protein 5 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of ARL6IP5 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 4:129,810,650...129,838,628
Ensembl chr 4:129,810,645...129,838,608
|
|
G |
Art4 |
ADP-ribosyltransferase 4 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of ART4 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 4:169,740,331...169,751,571
Ensembl chr 4:169,740,331...169,750,665
|
|
G |
Asap3 |
ArfGAP with SH3 domain, ankyrin repeat and PH domain 3 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of DDEFL1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 5:148,433,382...148,476,027
Ensembl chr 5:148,433,494...148,474,073
|
|
G |
Asb7 |
ankyrin repeat and SOCS box-containing 7 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of ASB7 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 1:120,222,835...120,267,411
Ensembl chr 1:120,222,745...120,267,282
|
|
G |
Asic4 |
acid sensing ion channel subunit family member 4 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of ASIC4 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 9:76,941,532...76,962,900
Ensembl chr 9:76,941,532...76,962,900
|
|
G |
Asph |
aspartate-beta-hydroxylase |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of ASPH mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 5:22,601,581...22,814,107
Ensembl chr 5:22,603,486...22,813,876
|
|
G |
Atf3 |
activating transcription factor 3 |
multiple interactions |
ISO |
Hydralazine inhibits the reaction [Ethanol results in increased expression of ATF3 mRNA] |
CTD |
PMID:28119953 |
|
NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631
|
|
G |
Atf4 |
activating transcription factor 4 |
multiple interactions |
ISO |
Hydralazine inhibits the reaction [Ethanol results in increased expression of ATF4 mRNA] |
CTD |
PMID:28119953 |
|
NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446
|
|
G |
Atg10 |
autophagy related 10 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of ATG10 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 2:22,109,304...22,398,313
Ensembl chr 2:22,108,426...22,398,233
|
|
G |
Atp13a4 |
ATPase 13A4 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of ATP13A4 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr11:71,222,196...71,359,933
Ensembl chr11:71,226,161...71,359,933
|
|
G |
Atp5f1e |
ATP synthase F1 subunit epsilon |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of ATP5F1E mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 3:163,259,072...163,261,974
Ensembl chr 3:163,260,476...163,261,450
|
|
G |
Atp5mc3 |
ATP synthase membrane subunit c locus 3 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of ATP5MC3 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 3:58,810,535...58,813,185
Ensembl chr 3:58,810,535...58,814,279
|
|
G |
Atp5me |
ATP synthase membrane subunit e |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of ATP5ME mRNA |
CTD |
PMID:17183730 |
|
NCBI chr14:1,319,868...1,320,996
Ensembl chr14:1,319,868...1,321,013
|
|
G |
Atp5pf |
ATP synthase peripheral stalk subunit F6 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of ATP5PF mRNA |
CTD |
PMID:17183730 |
|
NCBI chr11:23,881,594...23,889,581
Ensembl chr11:23,881,592...23,889,119
|
|
G |
Atp6ap1 |
ATPase H+ transporting accessory protein 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of ATP6AP1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr X:152,079,954...152,087,034
Ensembl chr X:152,079,865...152,087,034
|
|
G |
Atp6v1b1 |
ATPase H+ transporting V1 subunit B1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of ATP6V1B1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 4:116,223,799...116,242,475
Ensembl chr 4:116,223,799...116,242,475
|
|
G |
Atp6v1c1 |
ATPase H+ transporting V1 subunit C1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of ATP6V1C1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 7:69,834,464...69,872,278
Ensembl chr 7:69,834,463...69,872,278
|
|
G |
Atxn2 |
ataxin 2 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of ATXN2 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr12:34,754,132...34,851,175
Ensembl chr12:34,754,137...34,851,479
|
|
G |
Atxn7l1 |
ataxin 7-like 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of ATXN7L1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 6:49,759,876...49,982,323
Ensembl chr 6:49,759,883...49,982,320
|
|
G |
B9d1 |
B9 domain containing 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in decreased expression of B9D1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr10:46,186,222...46,196,309
Ensembl chr10:46,186,691...46,196,008
|
|
G |
Bad |
BCL2-associated agonist of cell death |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of BAD mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823
|
|
G |
Bag1 |
BAG cochaperone 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of BAG1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 5:56,068,494...56,081,075
Ensembl chr 5:56,068,494...56,081,075
|
|
G |
Bckdk |
branched chain ketoacid dehydrogenase kinase |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of BCKDK mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 1:182,515,335...182,520,007
Ensembl chr 1:182,515,327...182,536,633
|
|
G |
Bola1 |
bolA family member 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of BOLA1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 2:183,758,515...183,771,445
Ensembl chr 2:183,758,441...183,781,576
|
|
G |
Bpgm |
bisphosphoglycerate mutase |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of BPGM mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 4:63,139,730...63,168,581
Ensembl chr 4:63,140,018...63,168,581
|
|
G |
Bpifb2 |
BPI fold containing family B, member 2 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of BPIFB2 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 3:142,356,990...142,377,053
Ensembl chr 3:142,358,051...142,377,044
|
|
G |
Bptf |
bromodomain PHD finger transcription factor |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of BPTF mRNA |
CTD |
PMID:17183730 |
|
NCBI chr10:91,980,279...92,082,731
Ensembl chr10:91,982,758...92,082,769
|
|
G |
Brd8 |
bromodomain containing 8 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of BRD8 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr18:26,204,892...26,229,999
Ensembl chr18:26,181,732...26,229,884
|
|
G |
C1qtnf5 |
C1q and TNF related 5 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of C1QTNF5 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 8:44,450,934...44,453,075
Ensembl chr 8:44,451,154...44,453,074
|
|
G |
C4a |
complement C4A |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of C4A mRNA |
CTD |
PMID:17183730 |
|
NCBI chr20:4,005,731...4,020,083
Ensembl chr20:4,005,731...4,020,080
|
|
G |
C5h9orf152 |
similar to human chromosome 9 open reading frame 152 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of C9ORF152 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 5:72,660,573...72,667,941
Ensembl chr 5:72,660,573...72,668,379
|
|
G |
C8h3orf62 |
similar to human chromosome 3 open reading frame 62 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of C3ORF62 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 8:109,080,032...109,084,588
Ensembl chr 8:109,036,030...109,097,895
|
|
G |
C9h6orf132 |
similar to human chromosome 6 open reading frame 132 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of C6ORF132 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 9:13,524,822...13,561,756
Ensembl chr 9:13,525,395...13,561,585
|
|
G |
Cacng6 |
calcium voltage-gated channel auxiliary subunit gamma 6 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of CACNG6 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 1:65,732,910...65,747,377
Ensembl chr 1:65,732,632...65,747,341
|
|
G |
Camlg |
calcium modulating ligand |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of CAMLG mRNA |
CTD |
PMID:17183730 |
|
NCBI chr17:8,992,697...9,003,576
Ensembl chr17:8,992,696...9,003,552
|
|
G |
Canx |
calnexin |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of CANX mRNA |
CTD |
PMID:17183730 |
|
NCBI chr10:34,623,865...34,656,866
Ensembl chr10:34,625,191...34,656,821
|
|
G |
Car7 |
carbonic anhydrase 7 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of CA7 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr19:429,063...438,478
Ensembl chr19:429,075...438,467
|
|
G |
Car8 |
carbonic anhydrase 8 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in decreased expression of CA8 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 5:21,302,940...21,402,395
Ensembl chr 5:21,305,383...21,402,374
|
|
G |
Casd1 |
CAS1 domain containing 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of CASD1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 4:32,659,196...32,739,228
Ensembl chr 4:32,658,748...32,739,202
|
|
G |
Casp12 |
caspase 12 |
multiple interactions |
ISO |
Hydralazine inhibits the reaction [Ethanol results in increased cleavage of CASP12 protein] |
CTD |
PMID:28119953 |
|
NCBI chr 8:2,642,296...2,669,549
Ensembl chr 8:2,642,434...2,674,037
|
|
G |
Cbx7 |
chromobox 7 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of CBX7 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 7:111,460,656...111,479,231
Ensembl chr 7:111,460,656...111,477,973
|
|
G |
Ccdc138 |
coiled-coil domain containing 138 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of CCDC138 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr20:26,493,624...26,572,367
Ensembl chr20:26,495,235...26,572,376
|
|
G |
Ccdc146 |
coiled-coil domain containing 146 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in decreased expression of CCDC146 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 4:13,662,766...13,811,619
Ensembl chr 4:13,662,766...13,811,608
|
|
G |
Ccdc47 |
coiled-coil domain containing 47 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of CCDC47 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr10:91,130,303...91,148,829
Ensembl chr10:91,130,303...91,148,881
|
|
G |
Ccdc82 |
coiled-coil domain containing 82 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of CCDC82 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 8:10,227,727...10,265,963
Ensembl chr 8:10,228,430...10,265,963
|
|
G |
Ccl22 |
C-C motif chemokine ligand 22 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of CCL22 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr19:10,257,602...10,264,373
Ensembl chr19:10,257,601...10,264,400
|
|
G |
Ccl28 |
C-C motif chemokine ligand 28 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of CCL28 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 2:51,601,354...51,625,999
Ensembl chr 2:51,601,331...51,625,997
|
|
G |
Ccl4 |
C-C motif chemokine ligand 4 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of CCL4 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr10:68,466,394...68,468,229
Ensembl chr10:68,452,052...68,468,231
|
|
G |
Ccm2 |
CCM2 scaffold protein |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of CCM2 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr14:81,418,418...81,464,114
Ensembl chr14:81,418,236...81,464,116
|
|
G |
Cct2 |
chaperonin containing TCP1 subunit 2 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of CCT2 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 7:52,692,725...52,705,478
Ensembl chr 7:52,692,725...52,706,944
|
|
G |
Cct7 |
chaperonin containing TCP1 subunit 7 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of CCT7 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 4:117,989,232...118,006,478
Ensembl chr 4:117,989,232...118,006,580
|
|
G |
Cd63 |
Cd63 molecule |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of CD63 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 7:1,325,108...1,340,447
Ensembl chr 7:1,325,103...1,399,178
|
|
G |
Cdadc1 |
cytidine and dCMP deaminase domain containing 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of CDADC1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr15:33,726,590...33,755,611
Ensembl chr15:33,723,435...33,755,576
|
|
G |
Cdc37 |
cell division cycle 37, HSP90 cochaperone |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of CDC37 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 8:19,677,400...19,690,761
Ensembl chr 8:19,671,938...19,690,809
|
|
G |
Cdc42 |
cell division cycle 42 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of CDC42 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 5:149,555,069...149,593,239
Ensembl chr 5:149,553,724...149,593,111
|
|
G |
Cdk12 |
cyclin-dependent kinase 12 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of CDK12 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr10:83,201,177...83,256,906
Ensembl chr10:83,201,211...83,280,888 Ensembl chr10:83,201,211...83,280,888
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of CDK4 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 7:62,886,124...62,889,562
Ensembl chr 7:62,883,105...62,942,403
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
multiple interactions |
EXP |
[troglitazone co-treated with [Hydrochlorothiazide co-treated with Hydralazine co-treated with Reserpine]] results in decreased expression of CDKN1B protein |
CTD |
PMID:11318962 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
multiple interactions decreases methylation |
EXP ISO |
[Hydrochlorothiazide co-treated with Hydralazine co-treated with Reserpine] inhibits the reaction [Desoxycorticosterone Acetate affects the localization of CDKN2A protein]; [Hydrochlorothiazide co-treated with Hydralazine co-treated with Reserpine] inhibits the reaction [Desoxycorticosterone Acetate results in increased expression of CDKN2A mRNA] Hydralazine results in decreased methylation of CDKN2A promoter |
CTD |
PMID:15862127 PMID:18504326 |
|
NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149
|
|
G |
Cdr2 |
cerebellar degeneration-related protein 2 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of CDR2 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 1:175,502,837...175,527,746
Ensembl chr 1:175,502,838...175,537,472
|
|
G |
Cel |
carboxyl ester lipase |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of CEL mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 3:11,883,532...11,891,035
Ensembl chr 3:11,883,532...11,891,035
|
|
G |
Cenpn |
centromere protein N |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of CENPN mRNA |
CTD |
PMID:17183730 |
|
NCBI chr19:44,971,265...44,994,019
Ensembl chr19:44,968,308...44,994,012
|
|
G |
Cers5 |
ceramide synthase 5 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of CERS5 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 7:130,859,993...130,897,979
Ensembl chr 7:130,859,990...130,897,947
|
|
G |
Cfap300 |
cilia and flagella associated protein 300 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of CFAP300 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 8:5,180,180...5,198,840
Ensembl chr 8:5,180,675...5,198,807
|
|
G |
Chchd10 |
coiled-coil-helix-coiled-coil-helix domain containing 10 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of CHCHD10 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr20:12,725,839...12,727,638
Ensembl chr20:12,725,842...12,732,763
|
|
G |
Chchd2 |
coiled-coil-helix-coiled-coil-helix domain containing 2 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of CHCHD2 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr12:26,828,738...26,834,762
Ensembl chr12:26,828,736...26,834,755
|
|
G |
Chd2 |
chromodomain helicase DNA binding protein 2 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of CHD2 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 1:127,188,146...127,317,041
Ensembl chr 1:127,190,059...127,300,502
|
|
G |
Chmp5 |
charged multivesicular body protein 5 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of CHMP5 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 5:56,081,385...56,098,529
Ensembl chr 5:56,081,343...56,098,529
|
|
G |
Chn2 |
chimerin 2 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of CHN2 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 4:83,148,616...83,407,711
Ensembl chr 4:83,147,983...83,407,709
|
|
G |
Chrna1 |
cholinergic receptor nicotinic alpha 1 subunit |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of CHRNA1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 3:58,454,763...58,469,832
Ensembl chr 3:58,454,744...58,469,840
|
|
G |
Chst13 |
carbohydrate sulfotransferase 13 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of CHST13 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 4:122,824,022...122,837,940
Ensembl chr 4:122,824,022...122,838,019
|
|
G |
Cib1 |
calcium and integrin binding 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of CIB1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 1:134,178,331...134,183,895
Ensembl chr 1:134,178,331...134,213,423
|
|
G |
Clasp2 |
cytoplasmic linker associated protein 2 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of CLASP2 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 8:113,677,345...113,859,957
Ensembl chr 8:113,677,284...113,858,731
|
|
G |
Clcn5 |
chloride voltage-gated channel 5 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of CLCN5 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr X:15,185,380...15,339,977
Ensembl chr X:15,185,451...15,334,264
|
|
G |
Clybl |
citramalyl-CoA lyase |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of CLYBL mRNA |
CTD |
PMID:17183730 |
|
NCBI chr15:99,283,644...99,505,697
Ensembl chr15:99,283,650...99,505,695
|
|
G |
Cnnm3 |
cyclin and CBS domain divalent metal cation transport mediator 3 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of CNNM3 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 9:38,755,374...38,770,740
Ensembl chr 9:38,755,390...38,770,740
|
|
G |
Coa3 |
cytochrome C oxidase assembly factor 3 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of COA3 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr10:86,220,192...86,221,173
Ensembl chr10:86,220,194...86,221,178
|
|
G |
Cog5 |
component of oligomeric golgi complex 5 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of COG5 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 6:48,242,470...48,545,185
Ensembl chr 6:48,242,482...48,529,009
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
decreases expression decreases expression multiple interactions |
ISO EXP |
Hydralazine results in decreased expression of COL1A1 mRNA hydralazine decreases expression of Col1a1 mRNA in liver [Hydralazine co-treated with Valproic Acid] results in increased expression of COL1A1 mRNA |
CTD RGD |
PMID:8941590 PMID:17183730 PMID:33315911 |
RGD:407420266 |
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Col4a6 |
collagen type IV alpha 6 chain |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of COL4A6 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr X:104,766,463...105,117,499
Ensembl chr X:104,766,957...105,117,500
|
|
G |
Commd1 |
copper metabolism domain containing 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of COMMD1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr14:96,880,463...96,984,494
Ensembl chr14:96,880,463...96,984,501
|
|
G |
Commd6 |
COMM domain containing 6 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of COMMD6 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr15:78,467,333...78,474,382
Ensembl chr15:78,467,804...78,474,382
|
|
G |
Cope |
COPI coat complex subunit epsilon |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of COPE mRNA |
CTD |
PMID:17183730 |
|
NCBI chr16:19,114,871...19,125,076
Ensembl chr16:19,114,871...19,128,907
|
|
G |
Cops4 |
COP9 signalosome subunit 4 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of COPS4 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr14:9,078,579...9,108,788
Ensembl chr14:9,078,576...9,108,887
|
|
G |
Coq4 |
coenzyme Q4 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of COQ4 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 3:13,060,054...13,070,502
Ensembl chr 3:13,060,455...13,068,799
|
|
G |
Cox6b1 |
cytochrome c oxidase subunit 6B1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of COX6B1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 1:85,875,080...85,884,081
Ensembl chr 1:85,875,109...85,884,001 Ensembl chr 2:85,875,109...85,884,001 Ensembl chr 5:85,875,109...85,884,001
|
|
G |
Cox7c |
cytochrome c oxidase subunit 7C |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of COX7C mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 2:16,841,771...16,843,796
Ensembl chr 2:16,840,837...16,843,760
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
multiple interactions |
EXP |
Hydralazine inhibits the reaction [AGT protein results in decreased expression of CPT1A mRNA] |
CTD |
PMID:19109942 |
|
NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055
|
|
G |
Creb5 |
cAMP responsive element binding protein 5 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of CREB5 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 4:82,393,091...82,794,320
Ensembl chr 4:82,393,730...82,790,325
|
|
G |
Cryba4 |
crystallin, beta A4 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of CRYBA4 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr12:44,378,734...44,393,226
Ensembl chr12:44,378,737...44,393,221
|
|
G |
Ctcf |
CCCTC-binding factor |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in decreased expression of CTCF mRNA |
CTD |
PMID:17183730 |
|
NCBI chr19:33,521,726...33,571,124
Ensembl chr19:33,529,319...33,571,123
|
|
G |
Ctnnd1 |
catenin delta 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of CTNND1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 3:69,683,328...69,734,550
Ensembl chr 3:69,683,313...69,734,516
|
|
G |
Ctsk |
cathepsin K |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of CTSK mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 2:183,058,586...183,069,551
Ensembl chr 2:183,058,569...183,069,550
|
|
G |
Cuedc2 |
CUE domain containing 2 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of CUEDC2 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 1:245,192,057...245,200,594
Ensembl chr 1:245,192,063...245,200,339
|
|
G |
Cul1 |
cullin 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of CUL1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 4:76,551,952...76,625,830
Ensembl chr 4:76,551,983...76,627,980
|
|
G |
Cyb5r1 |
cytochrome b5 reductase 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of CYB5R1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr13:45,849,017...45,855,458
Ensembl chr13:45,849,091...45,855,458
|
|
G |
Cyb5r3 |
cytochrome b5 reductase 3 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of CYB5R3 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 7:114,306,686...114,324,247
Ensembl chr 7:114,306,685...114,324,298
|
|
G |
Cyfip2 |
cytoplasmic FMR1 interacting protein 2 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of CYFIP2 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr10:30,621,318...30,741,113
Ensembl chr10:30,621,318...30,741,113
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions |
EXP ISO |
Hydralazine inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein] |
CTD |
PMID:18493746 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions |
ISO EXP |
Hydralazine inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A2 protein] |
CTD |
PMID:18493746 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp2a3 |
cytochrome P450, family 2, subfamily a, polypeptide 3 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of CYP2A7 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 1:82,171,914...82,179,980
Ensembl chr 1:82,169,949...82,179,979
|
|
G |
Cyp4x1 |
cytochrome P450, family 4, subfamily x, polypeptide 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of CYP4X1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 5:128,651,681...128,683,338
Ensembl chr 5:128,651,776...128,682,779
|
|
G |
Dact2 |
dishevelled-binding antagonist of beta-catenin 2 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of DACT2 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 1:55,181,023...55,191,026
Ensembl chr 1:55,181,024...55,191,096
|
|
G |
Dancr |
differentiation antagonizing non-protein coding RNA |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of DANCR mRNA |
CTD |
PMID:17183730 |
|
NCBI chr14:34,126,956...34,127,936
|
|
G |
Dapk1 |
death associated protein kinase 1 |
decreases methylation increases expression |
ISO |
Hydralazine results in decreased methylation of DAPK1 promoter Hydralazine results in increased expression of DAPK1 mRNA |
CTD |
PMID:15862127 |
|
NCBI chr17:3,930,223...4,090,991
Ensembl chr17:3,930,213...4,090,991
|
|
G |
Dbf4b |
DBF4B-CDC7 kinase regulatory subunit |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of DBF4B mRNA |
CTD |
PMID:17183730 |
|
NCBI chr10:87,713,805...87,719,197
|
|
G |
Dbi |
diazepam binding inhibitor |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of DBI mRNA |
CTD |
PMID:17183730 |
|
NCBI chr13:31,241,466...31,249,853
Ensembl chr13:31,206,988...31,268,693
|
|
G |
Dcaf8 |
DDB1 and CUL4 associated factor 8 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of DCAF8 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr13:84,609,838...84,667,025
Ensembl chr13:84,610,248...84,669,726
|
|
G |
Dclre1c |
DNA cross-link repair 1C |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of DCLRE1C mRNA |
CTD |
PMID:17183730 |
|
NCBI chr17:74,775,828...74,810,089
Ensembl chr17:74,776,935...74,809,186
|
|
G |
Dcp1a |
decapping mRNA 1A |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of DCP1A mRNA |
CTD |
PMID:17183730 |
|
NCBI chr16:5,656,960...5,702,151
Ensembl chr16:5,656,773...5,702,140
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions |
ISO |
Hydralazine inhibits the reaction [Ethanol results in increased expression of DDIT3 mRNA]; Hydralazine inhibits the reaction [Ethanol results in increased expression of DDIT3 protein] |
CTD |
PMID:28119953 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Ddt |
D-dopachrome tautomerase |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of DDT mRNA |
CTD |
PMID:17183730 |
|
NCBI chr20:12,884,216...12,886,687
Ensembl chr20:12,884,243...12,888,482
|
|
G |
Ddx27 |
DEAD-box helicase 27 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of DDX27 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 3:155,744,182...155,763,380
Ensembl chr 3:155,744,150...155,763,372
|
|
G |
Ddx46 |
DEAD-box helicase 46 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of DDX46 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr17:8,942,070...8,988,440
Ensembl chr17:8,944,454...8,988,439
|
|
G |
Dlat |
dihydrolipoamide S-acetyltransferase |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in decreased expression of DLAT mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 8:50,979,151...51,004,435
Ensembl chr 8:50,978,051...51,004,479 Ensembl chr 1:50,978,051...51,004,479
|
|
G |
Dnaaf5 |
dynein, axonemal, assembly factor 5 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in decreased expression of DNAAF5 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr12:15,453,636...15,492,722
Ensembl chr12:15,453,636...15,492,739
|
|
G |
Dnah14 |
dynein axonemal heavy chain 14 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of DNAH14 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr13:93,322,653...93,540,706
Ensembl chr13:93,322,711...93,538,646
|
|
G |
Dnaja3 |
DnaJ heat shock protein family (Hsp40) member A3 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of DNAJA3 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr10:10,854,732...10,880,171
Ensembl chr10:10,854,732...10,880,161
|
|
G |
Dnajc3 |
DnaJ heat shock protein family (Hsp40) member C3 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of DNAJC3 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr15:96,025,605...96,068,585
Ensembl chr15:96,025,624...96,065,181
|
|
G |
Dnajc8 |
DnaJ heat shock protein family (Hsp40) member C8 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of DNAJC8 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 5:144,745,055...144,763,106
Ensembl chr 5:144,745,036...144,763,108
|
|
G |
Dnhd1 |
dynein heavy chain domain 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of DNHD1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 1:159,990,785...160,077,990
Ensembl chr 1:159,990,438...160,074,858
|
|
G |
Dpy19l3 |
dpy-19 like C-mannosyltransferase 3 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of DPY19L3 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 1:88,350,303...88,417,339
Ensembl chr 1:88,350,303...88,417,339
|
|
G |
Drd4 |
dopamine receptor D4 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of DRD4 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 1:196,396,366...196,400,824
Ensembl chr 1:196,396,366...196,399,553
|
|
G |
Dscc1 |
DNA replication and sister chromatid cohesion 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of DSCC1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 7:86,482,588...86,498,212
Ensembl chr 7:86,482,588...86,498,212
|
|
G |
Dync1li1 |
dynein cytoplasmic 1 light intermediate chain 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of DYNC1LI1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 8:114,376,649...114,410,297
Ensembl chr 8:114,376,662...114,410,934
|
|
G |
Dynll1 |
dynein light chain LC8-type 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of DYNLL1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr12:41,312,365...41,316,157
Ensembl chr12:41,312,367...41,314,741
|
|
G |
Edn1 |
endothelin 1 |
multiple interactions |
EXP |
Hydralazine inhibits the reaction [Nitric Oxide deficiency results in increased expression of EDN1 mRNA] |
CTD |
PMID:16326922 |
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Eef1d |
eukaryotic translation elongation factor 1 delta |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of EEF1D mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 7:107,581,930...107,596,735
Ensembl chr 7:107,581,930...107,608,799
|
|
G |
Efhb |
EF hand domain family, member B |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of EFHB mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 9:6,372,191...6,441,678
Ensembl chr 9:6,372,194...6,441,919
|
|
G |
Efhd2 |
EF-hand domain family, member D2 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of EFHD2 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 5:154,160,945...154,176,980
Ensembl chr 5:154,160,946...154,176,980
|
|
G |
Ehmt2 |
euchromatic histone lysine methyltransferase 2 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of EHMT2 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr20:3,919,623...3,936,751
Ensembl chr20:3,919,624...3,941,547
|
|
G |
Eif3l |
eukaryotic translation initiation factor 3, subunit L |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of EIF3L mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 7:110,652,565...110,663,614
Ensembl chr 7:110,627,107...110,663,614
|
|
G |
Eif4b |
eukaryotic translation initiation factor 4B |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of EIF4B mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 7:133,206,637...133,228,436
|
|
G |
Eif4g3 |
eukaryotic translation initiation factor 4 gamma, 3 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of EIF4G3 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 5:150,197,410...150,418,862
Ensembl chr 5:150,195,226...150,418,363
|
|
G |
Elk3 |
ETS transcription factor ELK3 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of ELK3 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 7:27,768,582...27,831,088
Ensembl chr 7:27,768,599...27,804,084
|
|
G |
Ell |
elongation factor for RNA polymerase II |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of ELL mRNA |
CTD |
PMID:17183730 |
|
NCBI chr16:18,843,775...18,891,484
Ensembl chr16:18,843,780...18,891,118
|
|
G |
Ell3 |
elongation factor for RNA polymerase II 3 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in decreased expression of ELL3 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 3:108,413,035...108,417,181
Ensembl chr 3:108,410,448...108,417,132
|
|
G |
Eln |
elastin |
multiple interactions |
EXP |
[Isoproterenol co-treated with Hydralazine] results in increased expression of ELN protein |
CTD |
PMID:3446201 |
|
NCBI chr12:21,968,544...22,011,929
Ensembl chr12:21,968,544...22,011,928
|
|
G |
Elob |
elongin B |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of ELOB mRNA |
CTD |
PMID:17183730 |
|
NCBI chr10:12,848,830...12,853,897
Ensembl chr10:12,848,827...12,853,635
|
|
G |
Elovl6 |
ELOVL fatty acid elongase 6 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of ELOVL6 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 2:218,063,682...218,174,767
Ensembl chr 2:218,063,804...218,171,186
|
|
G |
Emp3 |
epithelial membrane protein 3 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of EMP3 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 1:96,388,651...96,391,946
Ensembl chr 1:96,388,652...96,391,988
|
|
G |
Epas1 |
endothelial PAS domain protein 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of EPAS1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 6:7,790,236...7,871,717
Ensembl chr 6:7,790,647...7,871,228
|
|
G |
Epc1 |
enhancer of polycomb homolog 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of EPC1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr17:54,503,358...54,594,444
Ensembl chr17:54,503,358...54,594,425
|
|
G |
Epha8 |
Eph receptor A8 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of EPHA8 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 5:149,166,107...149,193,515
Ensembl chr 5:149,166,697...149,193,399
|
|
G |
Epn2 |
epsin 2 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of EPN2 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr10:46,197,785...46,259,673
Ensembl chr10:46,197,785...46,259,642
|
|
G |
Eprs1 |
glutamyl-prolyl-tRNA synthetase 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of EPRS1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr13:96,901,548...96,971,966
Ensembl chr13:96,901,575...96,971,966
|
|
G |
Erlec1 |
endoplasmic reticulum lectin 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of ERLEC1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr14:104,655,745...104,693,508
Ensembl chr14:104,655,673...104,693,480
|
|
G |
Ero1b |
endoplasmic reticulum oxidoreductase 1 beta |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of ERO1B mRNA |
CTD |
PMID:17183730 |
|
NCBI chr17:85,861,086...86,003,244
Ensembl chr17:85,929,618...86,003,398
|
|
G |
Esr1 |
estrogen receptor 1 |
decreases methylation multiple interactions increases expression |
ISO |
Hydralazine results in decreased methylation of ESR1 promoter Hydralazine inhibits the reaction [3-methylquinoline results in increased activity of ESR1 protein]; Hydralazine inhibits the reaction [8-methylquinoline results in increased activity of ESR1 protein] Hydralazine results in increased expression of ESR1 mRNA |
CTD |
PMID:15862127 PMID:30896932 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Etl4 |
enhancer trap locus 4 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of KIAA1217 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr17:82,841,075...83,304,868
Ensembl chr17:82,495,041...83,304,715
|
|
G |
Exoc3l2 |
exocyst complex component 3-like 2 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of EXOC3L2 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 1:79,113,784...79,145,359
Ensembl chr 1:79,112,506...79,145,465
|
|
G |
Exoc7 |
exocyst complex component 7 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of EXOC7 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr10:101,521,630...101,540,425
Ensembl chr10:101,520,927...101,540,561
|
|
G |
F11r |
F11 receptor |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of F11R mRNA |
CTD |
PMID:17183730 |
|
NCBI chr13:83,873,797...83,897,388
Ensembl chr13:83,873,797...83,897,402
|
|
G |
F12 |
coagulation factor XII |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of F12 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr17:9,207,683...9,215,530
Ensembl chr17:9,207,683...9,215,530
|
|
G |
Fam120a |
family with sequence similarity 120 member A |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of FAM120A mRNA |
CTD |
PMID:17183730 |
|
NCBI chr17:15,684,233...15,774,964
Ensembl chr17:15,684,233...15,774,964
|
|
G |
Fam13b |
family with sequence similarity 13, member B |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of FAM13B mRNA |
CTD |
PMID:17183730 |
|
NCBI chr18:26,040,285...26,107,112
Ensembl chr18:26,040,285...26,106,587
|
|
G |
Fam162a |
family with sequence similarity 162, member A |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of FAM162A mRNA |
CTD |
PMID:17183730 |
|
NCBI chr11:64,680,978...64,709,865
Ensembl chr11:64,680,323...64,711,239
|
|
G |
Fam163a |
family with sequence similarity 163, member A |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in decreased expression of FAM163A mRNA |
CTD |
PMID:17183730 |
|
NCBI chr13:68,262,867...68,341,323
Ensembl chr13:68,262,872...68,341,049
|
|
G |
Fam210b |
family with sequence similarity 210, member B |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of FAM210B mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 3:161,118,228...161,128,400
Ensembl chr 3:161,118,239...161,128,397
|
|
G |
Fam241b |
family with sequence similarity 241 member B |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of FAM241B mRNA |
CTD |
PMID:17183730 |
|
NCBI chr20:30,052,315...30,055,247
Ensembl chr20:30,052,324...30,055,084 Ensembl chr 6:30,052,324...30,055,084
|
|
G |
Fam3a |
FAM3 metabolism regulating signaling molecule A |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of FAM3A mRNA |
CTD |
PMID:17183730 |
|
NCBI chr X:152,166,716...152,175,327
Ensembl chr X:152,165,535...152,175,362
|
|
G |
Fam50a |
family with sequence similarity 50, member A |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of FAM50A mRNA |
CTD |
PMID:17183730 |
|
NCBI chr X:152,095,245...152,102,362
Ensembl chr X:152,095,245...152,102,362
|
|
G |
Faslg |
Fas ligand |
multiple interactions |
ISO EXP |
Hydralazine inhibits the reaction [Acrolein promotes the reaction [RELA protein binds to FASLG promoter]]; Hydralazine inhibits the reaction [Acrolein promotes the reaction [Zidovudine promotes the reaction [RELA protein binds to FASLG promoter]]]; Hydralazine inhibits the reaction [Acrolein promotes the reaction [Zidovudine results in increased expression of FASLG mRNA]]; Hydralazine inhibits the reaction [Acrolein results in increased expression of FASLG mRNA]; Hydralazine inhibits the reaction [Zidovudine promotes the reaction [Acrolein promotes the reaction [RELA protein binds to FASLG promoter]]]; Hydralazine inhibits the reaction [Zidovudine promotes the reaction [Acrolein results in increased expression of FASLG mRNA]]; Hydralazine inhibits the reaction [Zidovudine promotes the reaction [RELA protein binds to FASLG promoter]]; Hydralazine inhibits the reaction [Zidovudine results in increased expression of FASLG mRNA] Hydralazine inhibits the reaction [Acrolein promotes the reaction [Zidovudine results in increased expression of FASLG mRNA]]; Hydralazine inhibits the reaction [Acrolein results in increased expression of FASLG mRNA]; Hydralazine inhibits the reaction [Zidovudine promotes the reaction [Acrolein results in increased expression of FASLG mRNA]]; Hydralazine inhibits the reaction [Zidovudine results in increased expression of FASLG mRNA] |
CTD |
PMID:27238871 |
|
NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
|
|
G |
Fbrsl1 |
fibrosin-like 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of FBRSL1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr12:46,231,466...46,320,607
Ensembl chr12:46,231,495...46,320,357
|
|
G |
Fbxw4 |
F-box and WD repeat domain containing 4 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of FBXW4 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 1:244,426,892...244,514,188
Ensembl chr 1:244,426,896...244,514,163
|
|
G |
Fdps |
farnesyl diphosphate synthase |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of FDPS mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 2:174,497,402...174,507,031
Ensembl chr 2:174,486,665...174,507,776
|
|
G |
Ffar3 |
free fatty acid receptor 3 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of FFAR3 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 1:86,105,388...86,106,728
Ensembl chr 1:86,104,920...86,106,849
|
|
G |
Fhit |
fragile histidine triad diadenosine triphosphatase |
decreases methylation increases expression |
ISO |
Hydralazine results in decreased methylation of FHIT promoter Hydralazine results in increased expression of FHIT mRNA |
CTD |
PMID:15862127 |
|
NCBI chr15:13,935,029...15,442,620
Ensembl chr15:13,934,995...15,442,340
|
|
G |
Fis1 |
fission, mitochondrial 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of FIS1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr12:19,708,560...19,723,392
Ensembl chr12:19,708,558...19,723,377
|
|
G |
Flot1 |
flotillin 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of FLOT1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr20:2,917,864...2,927,993
Ensembl chr20:2,917,137...2,927,978
|
|
G |
Flt1 |
Fms related receptor tyrosine kinase 1 |
multiple interactions |
EXP |
[Hydralazine co-treated with Hydrochlorothiazide] inhibits the reaction [Cyclosporine results in increased expression of FLT1 mRNA] |
CTD |
PMID:12110003 |
|
NCBI chr12:7,296,899...7,468,626
Ensembl chr12:7,297,292...7,468,626
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
affects expression |
EXP |
Hydralazine affects the expression of FOS protein |
CTD |
PMID:8750937 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Foxp1 |
forkhead box P1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of FOXP1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 4:131,559,599...132,155,092
Ensembl chr 4:131,564,756...132,112,258
|
|
G |
Foxp2 |
forkhead box P2 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in decreased expression of FOXP2 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 4:43,133,827...43,712,442
Ensembl chr 4:43,133,912...43,711,683
|
|
G |
Foxp3 |
forkhead box P3 |
increases expression |
ISO |
Hydralazine results in increased expression of FOXP3 protein |
CTD |
PMID:19109157 |
|
NCBI chr X:14,908,494...14,924,994
Ensembl chr X:14,908,494...14,923,838
|
|
G |
Fst |
follistatin |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of FST mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 2:46,123,260...46,130,584
Ensembl chr 2:46,123,439...46,130,571
|
|
G |
Fstl5 |
follistatin-like 5 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of FSTL5 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 2:160,857,989...161,526,589
Ensembl chr 2:160,856,291...161,526,589
|
|
G |
Fth1 |
ferritin heavy chain 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of FTH1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 1:206,627,142...206,629,430
Ensembl chr 1:206,627,103...206,725,424
|
|
G |
Fthl17a |
ferritin, heavy polypeptide-like 17, member A |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of FTHL17 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr X:49,595,422...49,596,399
Ensembl chr X:49,595,718...49,596,266
|
|
G |
Fxyd5 |
FXYD domain-containing ion transport regulator 5 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of FXYD5 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 1:86,267,937...86,277,329
Ensembl chr 1:86,267,406...86,277,519
|
|
G |
Gabarap |
GABA type A receptor-associated protein |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of GABARAP mRNA |
CTD |
PMID:17183730 |
|
NCBI chr10:54,714,777...54,718,099
Ensembl chr10:54,714,198...54,717,765
|
|
G |
Galnt7 |
polypeptide N-acetylgalactosaminyltransferase 7 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of GALNT7 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr16:32,578,643...32,703,189
Ensembl chr16:32,578,690...32,702,690
|
|
G |
Galp |
galanin-like peptide |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of GALP mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 1:67,684,023...67,703,121
Ensembl chr 1:67,684,025...67,702,269
|
|
G |
Gamt |
guanidinoacetate N-methyltransferase |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of GAMT mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 7:9,448,590...9,451,413
Ensembl chr 7:9,448,628...9,451,778
|
|
G |
Ganab |
glucosidase II alpha subunit |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of GANAB mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 1:205,793,910...205,813,704
Ensembl chr 1:205,793,895...205,813,695
|
|
G |
Gatd3a |
glutamine amidotransferase class 1 domain containing 3A |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of GATD3 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr20:10,514,793...10,522,894
Ensembl chr20:10,514,744...10,522,885
|
|
G |
Gfra2 |
GDNF family receptor alpha 2 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of GFRA2 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr15:45,941,841...46,033,715
Ensembl chr15:45,941,828...46,033,714
|
|
G |
Gfra3 |
GDNF family receptor alpha 3 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of GFRA3 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr18:26,297,828...26,326,105
Ensembl chr18:26,297,829...26,326,105
|
|
G |
Gjd4 |
gap junction protein, delta 4 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of GJD4 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr17:57,348,844...57,352,601
Ensembl chr17:57,349,877...57,352,446
|
|
G |
Gla |
galactosidase, alpha |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of GLA mRNA |
CTD |
PMID:17183730 |
|
NCBI chr X:97,769,227...97,780,646
Ensembl chr X:97,768,996...97,780,664
|
|
G |
Gnpat |
glyceronephosphate O-acyltransferase |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of GNPAT mRNA |
CTD |
PMID:17183730 |
|
NCBI chr19:52,822,326...52,848,872
Ensembl chr19:52,822,319...52,852,361
|
|
G |
Golgb1 |
golgin B1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of GOLGB1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr11:63,843,179...63,900,665
Ensembl chr11:63,843,986...63,900,770
|
|
G |
Golm2 |
golgi membrane protein 2 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of GOLM2 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 3:108,827,017...108,896,207
Ensembl chr 3:108,827,047...108,896,207
|
|
G |
Gp2 |
glycoprotein 2 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of GP2 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 1:173,797,057...173,812,619
Ensembl chr 1:173,797,057...173,812,619
|
|
G |
Gpaa1 |
glycosylphosphatidylinositol anchor attachment 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in decreased expression of GPAA1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 7:108,051,896...108,055,479
Ensembl chr 7:108,051,861...108,055,484
|
|
G |
Gpbp1l1 |
GC-rich promoter binding protein 1-like 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of GPBP1L1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 5:130,009,768...130,050,636
Ensembl chr 5:130,023,137...130,050,459
|
|
G |
Gpr83 |
G protein-coupled receptor 83 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of GPR83 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 8:11,693,540...11,704,028
Ensembl chr 8:11,693,540...11,704,028
|
|
G |
Gps2 |
G protein pathway suppressor 2 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of GPS2 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr10:54,637,360...54,640,542
Ensembl chr10:54,637,455...54,640,650
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
ISO |
Hydralazine inhibits the reaction [Ethanol results in increased expression of GPT protein] |
CTD |
PMID:28119953 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Grap |
GRB2-related adaptor protein |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of GRAP mRNA |
CTD |
PMID:17183730 |
|
NCBI chr10:46,298,965...46,352,057
Ensembl chr10:46,332,909...46,352,056
|
|
G |
Grk3 |
G protein-coupled receptor kinase 3 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in decreased expression of GRK3 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr12:43,624,778...43,735,375
Ensembl chr12:43,624,897...43,731,262
|
|
G |
Grk4 |
G protein-coupled receptor kinase 4 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of GRK4 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr14:75,998,554...76,080,808
Ensembl chr14:76,006,218...76,080,693
|
|
G |
Grwd1 |
glutamate-rich WD repeat containing 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of GRWD1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 1:96,301,260...96,306,962
Ensembl chr 1:96,301,261...96,307,201
|
|
G |
Gsn |
gelsolin |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of GSN mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 3:18,585,166...18,638,404
Ensembl chr 3:18,585,172...18,638,402
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
decreases methylation increases expression |
ISO |
Hydralazine results in decreased methylation of GSTP1 promoter Hydralazine results in increased expression of GSTP1 mRNA |
CTD |
PMID:15862127 |
|
NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226
|
|
G |
Gstt2 |
glutathione S-transferase theta 2 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of GSTT2 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr20:12,819,617...12,823,288
Ensembl chr20:12,819,170...12,823,288
|
|
G |
Guk1 |
guanylate kinase 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of GUK1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr10:43,971,514...43,988,658
Ensembl chr10:43,971,509...43,980,107
|
|
G |
H3f3a |
H3.3 histone A |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of H3-3A mRNA |
CTD |
PMID:17183730 |
|
NCBI chr13:92,533,289...92,544,902
Ensembl chr13:92,533,298...92,544,908
|
|
G |
Haao |
3-hydroxyanthranilate 3,4-dioxygenase |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of HAAO mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 6:10,845,235...10,864,863
Ensembl chr 6:10,845,771...10,864,877
|
|
G |
Hba-a2 |
hemoglobin alpha, adult chain 2 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in decreased expression of HBA1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr10:15,323,830...15,324,677
Ensembl chr10:15,307,815...15,338,392 Ensembl chr10:15,307,815...15,338,392
|
|
G |
Hbb |
hemoglobin subunit beta |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in decreased expression of HBB mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 1:158,250,421...158,251,832
Ensembl chr 1:158,120,200...158,252,012
|
|
G |
Hbz |
hemoglobin subunit zeta |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in decreased expression of HBZ mRNA |
CTD |
PMID:17183730 |
|
NCBI chr10:15,343,821...15,345,301
Ensembl chr10:15,343,831...15,345,312
|
|
G |
Hcfc1r1 |
host cell factor C1 regulator 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of HCFC1R1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr10:12,705,139...12,706,852
Ensembl chr10:12,705,077...12,706,850
|
|
G |
Hdgfl1 |
HDGF like 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of HDGFL1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr17:38,207,906...38,209,902
|
|
G |
Heatr5b |
HEAT repeat containing 5B |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in decreased expression of HEATR5B mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 6:16,243,424...16,323,444
Ensembl chr 6:16,243,461...16,323,435
|
|
G |
Hebp1 |
heme binding protein 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of HEBP1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 4:167,974,316...168,003,854
Ensembl chr 4:167,974,319...168,003,854
|
|
G |
Henmt1 |
HEN methyltransferase 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of HENMT1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 2:196,585,732...196,603,700
Ensembl chr 2:196,586,797...196,599,738
|
|
G |
Hfe |
homeostatic iron regulator |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of HFE mRNA |
CTD |
PMID:17183730 |
|
NCBI chr17:41,413,451...41,421,502
Ensembl chr17:41,413,451...41,421,502
|
|
G |
Higd2a |
HIG1 hypoxia inducible domain family, member 2A |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of HIGD2A mRNA |
CTD |
PMID:17183730 |
|
NCBI chr17:10,021,853...10,022,777
Ensembl chr17:10,021,859...10,022,796
|
|
G |
Hinfp |
histone H4 transcription factor |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of HINFP mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 8:44,634,333...44,644,288
Ensembl chr 8:44,634,333...44,641,000
|
|
G |
Hint1 |
histidine triad nucleotide binding protein 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of HINT1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr10:38,989,516...38,993,259
Ensembl chr 4:92,100,973...92,101,568
|
|
G |
Hint2 |
histidine triad nucleotide binding protein 2 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of HINT2 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 5:57,904,613...57,906,868
Ensembl chr 5:57,904,614...57,907,097
|
|
G |
Hk1 |
hexokinase 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of HK1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr20:30,230,488...30,332,099
Ensembl chr20:30,230,486...30,332,131
|
|
G |
Hmgcl |
3-hydroxy-3-methylglutaryl-CoA lyase |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of HMGCL mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 5:148,178,203...148,192,072
Ensembl chr 5:148,178,252...148,192,068
|
|
G |
Hmgxb4 |
HMG-box containing 4 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of HMGXB4 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr19:13,364,741...13,403,563
Ensembl chr19:13,364,807...13,403,563
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
ISO |
Hydralazine inhibits the reaction [[Acrolein binds to ALB protein] which results in increased expression of HMOX1 mRNA] |
CTD |
PMID:32530271 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hps3 |
HPS3, biogenesis of lysosomal organelles complex 2 subunit 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of HPS3 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 2:102,484,574...102,527,580
Ensembl chr 2:102,484,574...102,526,047
|
|
G |
Hpse |
heparanase |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of HPSE mRNA |
CTD |
PMID:17183730 |
|
NCBI chr14:8,896,593...8,937,011
Ensembl chr14:8,896,593...8,937,010
|
|
G |
Hsbp1 |
heat shock factor binding protein 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of HSBP1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr19:47,401,039...47,405,373
Ensembl chr19:47,400,966...47,435,821
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions |
ISO |
Hydralazine inhibits the reaction [Ethanol results in increased expression of HSPA5 mRNA] |
CTD |
PMID:28119953 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Hspa8 |
heat shock protein family A (Hsp70) member 8 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of HSPA8 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 8:41,183,397...41,187,260
Ensembl chr 8:41,183,264...41,187,259
|
|
G |
Hyi |
hydroxypyruvate isomerase |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of HYI mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 5:131,894,575...131,897,709
Ensembl chr 5:131,894,598...131,897,251
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of ICAM1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Icmt |
isoprenylcysteine carboxyl methyltransferase |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of ICMT mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 5:162,804,368...162,811,129
Ensembl chr 5:162,804,368...162,811,128
|
|
G |
Idh3g |
isocitrate dehydrogenase (NAD(+)) 3 non-catalytic subunit gamma |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of IDH3G mRNA |
CTD |
PMID:17183730 |
|
NCBI chr X:151,515,244...151,524,175
Ensembl chr X:151,515,247...151,524,171
|
|
G |
Ifitm2 |
interferon induced transmembrane protein 2 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of IFITM2 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 1:196,051,539...196,052,719
Ensembl chr 1:196,051,537...196,052,741
|
|
G |
Ifrd1 |
interferon-related developmental regulator 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of IFRD1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 6:57,269,395...57,317,833
Ensembl chr 6:57,269,384...57,288,990
|
|
G |
Ift22 |
intraflagellar transport 22 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of IFT22 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr12:19,759,072...19,768,859
Ensembl chr12:19,761,790...19,768,809
|
|
G |
Ift57 |
intraflagellar transport 57 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of IFT57 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr11:51,051,520...51,124,909
Ensembl chr11:51,059,611...51,124,812
|
|
G |
Igbp1 |
immunoglobulin binding protein 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of IGBP1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr X:65,582,832...65,605,078
Ensembl chr X:65,582,821...65,606,049
|
|
G |
Igf2bp2 |
insulin-like growth factor 2 mRNA binding protein 2 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of IGF2BP2 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr11:78,874,402...78,974,392
Ensembl chr11:78,874,414...78,974,377
|
|
G |
Il10 |
interleukin 10 |
increases secretion |
ISO |
Hydralazine results in increased secretion of IL10 protein |
CTD |
PMID:16612254 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il1rapl2 |
interleukin 1 receptor accessory protein-like 2 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of IL1RAPL2 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr X:100,961,509...102,271,753
Ensembl chr X:100,961,812...102,271,753
|
|
G |
Il3 |
interleukin 3 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in decreased expression of IL3 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr10:38,405,716...38,408,066
Ensembl chr10:38,405,716...38,408,066
|
|
G |
Il6 |
interleukin 6 |
decreases secretion increases expression |
ISO |
Hydralazine results in decreased secretion of IL6 protein Hydralazine results in increased expression of IL6 protein |
CTD |
PMID:16612254 PMID:19575532 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Inava |
innate immunity activator |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of INAVA mRNA |
CTD |
PMID:17183730 |
|
NCBI chr13:47,666,446...47,687,383
Ensembl chr13:47,666,447...47,686,729
|
|
G |
Ino80e |
INO80 complex subunit E |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of INO80E mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 1:181,461,406...181,472,059
Ensembl chr 1:181,461,408...181,472,469
|
|
G |
Irf7 |
interferon regulatory factor 7 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of IRF7 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 1:196,367,380...196,370,943
Ensembl chr 1:196,367,361...196,370,832
|
|
G |
Irx3 |
iroquois homeobox 3 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of IRX3 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr19:15,211,882...15,215,317
Ensembl chr19:15,211,878...15,215,317
|
|
G |
Isca2 |
iron-sulfur cluster assembly 2 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of ISCA2 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 6:104,418,509...104,420,019
Ensembl chr 6:104,418,454...104,420,045 Ensembl chr14:104,418,454...104,420,045
|
|
G |
Itgam |
integrin subunit alpha M |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in decreased expression of ITGAM mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 1:182,659,047...182,709,501
Ensembl chr 1:182,659,000...182,709,503
|
|
G |
Itsn1 |
intersectin 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of ITSN1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr11:30,978,590...31,160,645
Ensembl chr11:30,978,590...31,160,645
|
|
G |
Itsn2 |
intersectin 2 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of ITSN2 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 6:27,616,645...27,727,373
Ensembl chr 6:27,600,406...27,727,124
|
|
G |
Jarid2 |
jumonji and AT-rich interaction domain containing 2 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of JARID2 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr17:19,777,487...19,957,696
Ensembl chr17:19,777,266...19,955,690
|
|
G |
Jmjd1c |
jumonji domain containing 1C |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of JMJD1C mRNA |
CTD |
PMID:17183730 |
|
NCBI chr20:21,332,147...21,494,220
Ensembl chr20:21,332,147...21,463,122
|
|
G |
Kank1 |
KN motif and ankyrin repeat domains 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of KANK1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 1:222,877,962...223,074,514
Ensembl chr 1:222,877,622...223,074,514
|
|
G |
Kank4 |
KN motif and ankyrin repeat domains 4 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of KANK4 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 5:113,401,491...113,465,526
Ensembl chr 5:113,402,468...113,465,555
|
|
G |
Kcna7 |
potassium voltage-gated channel subfamily A member 7 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in decreased expression of KCNA7 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 1:95,886,073...95,891,565
Ensembl chr 1:95,886,073...95,891,565
|
|
G |
Kdelr3 |
KDEL endoplasmic reticulum protein retention receptor 3 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of KDELR3 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 7:111,079,236...111,089,463
Ensembl chr 7:111,079,218...111,101,600
|
|
G |
Kiaa0586 |
KIAA0586 homolog |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of KIAA0586 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 6:89,622,711...89,725,951
Ensembl chr 6:89,623,699...89,725,962
|
|
G |
Klf6 |
KLF transcription factor 6 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of KLF6 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr17:64,539,456...64,548,451
Ensembl chr17:64,531,463...64,588,570
|
|
G |
Klhl9 |
kelch-like family member 9 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of KLHL9 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 5:103,333,747...103,337,931
|
|
G |
Krt17 |
keratin 17 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in decreased expression of KRT17 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr10:85,178,673...85,183,392
Ensembl chr10:85,178,675...85,183,392
|
|
G |
Lasp1 |
LIM and SH3 protein 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of LASP1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr10:82,795,177...82,835,659
Ensembl chr10:82,795,137...82,943,292
|
|
G |
Lef1 |
lymphoid enhancer binding factor 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of LEF1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 2:219,666,549...219,779,815
Ensembl chr 2:219,666,592...219,779,794
|
|
G |
Lgals1 |
galectin 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of LGALS1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 7:110,485,239...110,488,345
Ensembl chr 7:110,481,392...110,488,345
|
|
G |
Lgals2 |
galectin 2 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of LGALS2 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 7:110,403,171...110,410,046
Ensembl chr 7:110,403,173...110,404,802
|
|
G |
Lgr4 |
leucine-rich repeat-containing G protein-coupled receptor 4 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of LGR4 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 3:96,447,385...96,550,006
Ensembl chr 3:96,447,858...96,548,899
|
|
G |
Lhfpl5 |
LHFPL tetraspan subfamily member 5 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of LHFPL5 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr20:6,632,324...6,642,534
Ensembl chr20:6,632,362...6,642,532
|
|
G |
Lin37 |
lin-37 DREAM MuvB core complex component |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of LIN37 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 1:85,809,065...85,813,235
Ensembl chr 1:85,809,074...85,812,991
|
|
G |
LOC103693823 |
epididymal secretory protein E3-beta-like |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of EDDM3A mRNA |
CTD |
PMID:17183730 |
|
NCBI chr15:24,385,585...24,386,643
Ensembl chr15:24,386,192...24,386,623
|
|
G |
Lpcat4 |
lysophosphatidylcholine acyltransferase 4 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of LPCAT4 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 3:99,044,729...99,052,963
Ensembl chr 3:99,044,729...99,052,875
|
|
G |
Lpgat1 |
lysophosphatidylglycerol acyltransferase 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of LPGAT1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr13:103,294,622...103,365,372
Ensembl chr13:103,294,528...103,362,333
|
|
G |
Lpin3 |
lipin 3 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of LPIN3 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 3:149,533,719...149,558,494
Ensembl chr 3:149,534,051...149,558,327
|
|
G |
Lpp |
LIM domain containing preferred translocation partner in lipoma |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of LPP mRNA |
CTD |
PMID:17183730 |
|
NCBI chr11:75,787,326...76,426,646
Ensembl chr11:75,797,078...76,422,597
|
|
G |
Lrfn1 |
leucine rich repeat and fibronectin type III domain containing 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of LRFN1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 1:83,742,442...83,761,450
Ensembl chr 1:83,682,964...83,761,449
|
|
G |
Lrp10 |
LDL receptor related protein 10 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of LRP10 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr15:27,921,335...27,927,507
Ensembl chr15:27,920,259...27,927,505
|
|
G |
Lrrc40 |
leucine rich repeat containing 40 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of LRRC40 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 2:247,101,518...247,131,061
Ensembl chr 2:247,101,500...247,131,059
|
|
G |
Lrrc8e |
leucine rich repeat containing 8 VRAC subunit E |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of LRRC8E mRNA |
CTD |
PMID:17183730 |
|
NCBI chr12:2,578,240...2,589,407
Ensembl chr12:2,578,315...2,589,412
|
|
G |
Luc7l3 |
LUC7-like 3 pre-mRNA splicing factor |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of CROP mRNA |
CTD |
PMID:17183730 |
|
NCBI chr10:79,240,050...79,276,555
Ensembl chr10:79,240,563...79,276,538
|
|
G |
Ly86 |
lymphocyte antigen 86 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of LY86 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr17:27,415,807...27,499,695
Ensembl chr17:27,415,830...27,487,260
|
|
G |
Maoa |
monoamine oxidase A |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of MAOA mRNA |
CTD |
PMID:17183730 |
|
NCBI chr X:6,032,172...6,098,308
Ensembl chr X:6,030,795...6,099,593
|
|
G |
Map2k3 |
mitogen activated protein kinase kinase 3 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of MAP2K3 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr10:45,608,145...45,629,492
Ensembl chr10:45,607,163...45,629,492
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
EXP |
Hydralazine inhibits the reaction [AGT protein modified form results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:16344371 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
EXP |
Hydralazine inhibits the reaction [AGT protein modified form results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:16344371 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mark3 |
microtubule affinity regulating kinase 3 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of MARK3 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 6:130,626,612...130,716,245
Ensembl chr 6:130,627,482...130,716,647
|
|
G |
Mas1 |
MAS1 proto-oncogene, G protein-coupled receptor |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of MAS1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 1:47,879,956...47,911,500
Ensembl chr 1:47,880,309...47,911,709
|
|
G |
Mbd6 |
methyl-CpG binding domain protein 6 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of MBD6 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 7:63,107,562...63,115,841
Ensembl chr 7:63,107,562...63,113,274
|
|
G |
Mboat7 |
membrane bound O-acyltransferase domain containing 7 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of MBOAT7 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 1:65,525,206...65,539,538
Ensembl chr 1:65,525,213...65,539,538
|
|
G |
Me2 |
malic enzyme 2 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of ME2 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr18:67,350,833...67,400,987
Ensembl chr18:67,355,795...67,400,987
|
|
G |
Med8 |
mediator complex subunit 8 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of MED8 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 5:131,948,632...131,949,516
Ensembl chr 5:131,943,982...131,950,305
|
|
G |
Mettl3 |
methyltransferase 3, N6-adenosine-methyltransferase complex catalytic subunit |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of METTL3 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr15:25,002,505...25,014,097
Ensembl chr15:25,003,172...25,014,041
|
|
G |
Mettl6 |
methyltransferase 6, tRNA N3-cytidine |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of METTL6 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr16:6,683,820...6,699,013
Ensembl chr16:6,583,465...6,698,975
|
|
G |
Mfsd5 |
major facilitator superfamily domain containing 5 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of MFSD5 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 7:133,409,096...133,411,377
Ensembl chr 7:133,402,537...133,411,396
|
|
G |
Mgat1 |
alpha-1,3-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of MGAT1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr10:33,563,642...33,582,718
Ensembl chr10:33,561,388...33,591,503
|
|
G |
Mgmt |
O-6-methylguanine-DNA methyltransferase |
decreases methylation increases expression |
ISO |
Hydralazine results in decreased methylation of MGMT promoter Hydralazine results in increased expression of MGMT mRNA |
CTD |
PMID:15862127 |
|
NCBI chr 1:191,710,980...191,937,760
Ensembl chr 1:191,710,930...191,937,756
|
|
G |
Mgp |
matrix Gla protein |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of MGP mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 4:169,766,290...169,769,612
Ensembl chr 4:169,766,279...169,769,667
|
|
G |
Mical3 |
microtubule associated monooxygenase, calponin and LIM domain containing 3 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of MICAL3 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 4:154,152,776...154,353,274
Ensembl chr 4:154,153,834...154,302,590
|
|
G |
Micos13 |
mitochondrial contact site and cristae organizing system subunit 13 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of MICOS13 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 9:1,439,841...1,441,782
Ensembl chr 9:1,439,058...1,442,076
|
|
G |
Mis12 |
MIS12 kinetochore complex component |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of MIS12 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr10:55,739,741...55,747,915
Ensembl chr10:55,739,564...55,751,068
|
|
G |
Mks1 |
MKS transition zone complex subunit 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of MKS1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr10:72,655,921...72,667,007
Ensembl chr10:72,655,921...72,666,655
|
|
G |
Mllt10 |
MLLT10, histone lysine methyltransferase DOT1L cofactor |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of MLLT10 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr17:80,821,870...80,949,349
Ensembl chr17:80,822,556...80,949,345
|
|
G |
Mmab |
metabolism of cobalamin associated B |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of MMAB mRNA |
CTD |
PMID:17183730 |
|
NCBI chr12:42,159,109...42,172,518
Ensembl chr12:42,159,089...42,172,490
|
|
G |
Mme |
membrane metallo-endopeptidase |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of MME mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 2:147,686,913...147,803,808
Ensembl chr 2:147,722,086...147,803,792
|
|
G |
Mmp10 |
matrix metallopeptidase 10 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of MMP10 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 8:4,689,840...4,697,748
Ensembl chr 8:4,689,840...4,697,748
|
|
G |
Mmp25 |
matrix metallopeptidase 25 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of MMP25 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr10:12,661,297...12,676,119
Ensembl chr10:12,661,208...12,675,871
|
|
G |
Mpst |
mercaptopyruvate sulfurtransferase |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of MPST mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 7:109,955,581...109,963,155
Ensembl chr 7:109,955,675...109,963,141
|
|
G |
Mrnip |
MRN complex interacting protein |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of MRNIP mRNA |
CTD |
PMID:17183730 |
|
NCBI chr10:34,501,359...34,525,474
Ensembl chr10:34,501,384...34,525,469
|
|
G |
mrpl11 |
mitochondrial ribosomal protein L11 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of MRPL11 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 1:202,264,419...202,267,288
Ensembl chr 1:202,264,471...202,267,756
|
|
G |
Mrpl39 |
mitochondrial ribosomal protein L39 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of MRPL39 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr11:23,779,655...23,795,146
Ensembl chr11:23,779,662...23,795,125
|
|
G |
Mrpl45 |
mitochondrial ribosomal protein L45 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of MRPL45 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr10:82,308,650...82,320,474
Ensembl chr10:82,308,427...82,320,474
|
|
G |
Mrpl53 |
mitochondrial ribosomal protein L53 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of MRPL53 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 4:115,615,329...115,616,219
|
|
G |
Mrps12 |
mitochondrial ribosomal protein S12 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of MRPS12 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 1:84,025,896...84,028,896
Ensembl chr 1:84,025,899...84,028,780
|
|
G |
Mrps18a |
mitochondrial ribosomal protein S18A |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of MRPS18A mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 9:14,853,322...14,869,819
Ensembl chr 9:14,853,291...14,869,835
|
|
G |
Mrps24 |
mitochondrial ribosomal protein S24 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of MRPS24 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr14:80,584,671...80,588,801
Ensembl chr14:80,584,673...80,588,871
|
|
G |
Mrps5 |
mitochondrial ribosomal protein S5 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of MRPS5 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 3:114,821,046...114,837,291
Ensembl chr 3:114,821,046...114,837,291
|
|
G |
Mrrf |
mitochondrial ribosome recycling factor |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of MRRF mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 3:19,487,124...19,543,911
Ensembl chr 3:19,487,182...19,543,908
|
|
G |
Mta3 |
metastasis associated 1 family, member 3 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of MTA3 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 6:10,867,028...10,987,221
Ensembl chr 6:10,867,011...10,986,883
|
|
G |
Mtmr4 |
myotubularin related protein 4 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of MTMR4 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr10:72,393,411...72,416,342
Ensembl chr10:72,392,551...72,416,342
|
|
G |
Muc1 |
mucin 1, cell surface associated |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of MUC1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 2:174,635,989...174,640,738
Ensembl chr 2:174,635,995...174,640,733
|
|
G |
Mybl2 |
MYB proto-oncogene like 2 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of MYBL2 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 3:151,705,254...151,733,714
Ensembl chr 3:151,705,288...151,733,708
|
|
G |
Mycbp2 |
MYC binding protein 2 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of MYCBP2 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr15:79,937,354...80,175,432
Ensembl chr15:79,937,354...80,175,498
|
|
G |
Myh7 |
myosin heavy chain 7 |
multiple interactions |
EXP |
Hydralazine inhibits the reaction [Nitric Oxide deficiency results in increased expression of MYH7 mRNA] |
CTD |
PMID:16326922 |
|
NCBI chr15:28,446,550...28,469,888
Ensembl chr15:28,446,550...28,468,217
|
|
G |
Myl6b |
myosin light chain 6B |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of MYL6B mRNA |
CTD |
PMID:17183730 |
|
NCBI chr X:40,572,012...40,572,991
|
|
G |
Myom1 |
myomesin 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of MYOM1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 9:110,916,156...111,039,344
Ensembl chr 9:110,915,943...111,039,344
|
|
G |
Myot |
myotilin |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of MYOT mRNA |
CTD |
PMID:17183730 |
|
NCBI chr18:36,705,244...36,724,849
Ensembl chr18:36,705,314...36,724,841
|
|
G |
Naa10 |
N(alpha)-acetyltransferase 10, NatA catalytic subunit |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of NAA10 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr X:151,656,056...151,661,304
Ensembl chr X:151,656,056...151,661,252
|
|
G |
Naa38 |
N(alpha)-acetyltransferase 38, NatC auxiliary subunit |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of NAA38 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr10:54,117,754...54,118,913
Ensembl chr10:54,117,163...54,119,494
|
|
G |
Nalcn |
sodium leak channel, non-selective |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of NALCN mRNA |
CTD |
PMID:17183730 |
|
NCBI chr15:100,398,583...100,741,243
Ensembl chr15:100,398,615...100,741,001
|
|
G |
Nalf2 |
NALCN channel auxiliary factor 2 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of NALF2 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr X:64,925,100...64,951,074
Ensembl chr X:64,925,051...64,951,077
|
|
G |
Nampt |
nicotinamide phosphoribosyltransferase |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in decreased expression of NAMPT mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 6:49,425,316...49,462,109
Ensembl chr 6:49,424,332...49,462,100
|
|
G |
Nap1l1 |
nucleosome assembly protein 1-like 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of NAP1L1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 7:46,933,278...46,957,853
Ensembl chr 7:46,933,356...46,956,593
|
|
G |
Nat2 |
N-acetyltransferase 2 |
increases acetylation affects metabolic processing |
ISO |
NAT2 protein results in increased acetylation of Hydralazine NAT2 protein affects the metabolism of Hydralazine |
CTD |
PMID:15627487 |
|
NCBI chr16:22,207,362...22,238,513
Ensembl chr16:22,208,194...22,238,520
|
|
G |
Nbeal1 |
neurobeachin-like 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of NBEAL1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 9:61,575,154...61,743,896
Ensembl chr 9:61,575,356...61,736,750
|
|
G |
Nbr1 |
NBR1, autophagy cargo receptor |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in decreased expression of NBR1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr10:86,477,775...86,506,418
Ensembl chr10:86,478,290...86,506,412
|
|
G |
Ncf1 |
neutrophil cytosolic factor 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of NCF1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr12:22,485,382...22,494,647
Ensembl chr12:22,485,451...22,494,646
|
|
G |
Ncoa4 |
nuclear receptor coactivator 4 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of NCOA4 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr16:7,389,222...7,409,564
Ensembl chr16:7,366,542...7,409,641 Ensembl chr16:7,366,542...7,409,641
|
|
G |
Ncor1 |
nuclear receptor co-repressor 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of NCOR1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr10:46,999,536...47,142,294
Ensembl chr10:46,999,536...47,141,032
|
|
G |
Ncr1 |
natural cytotoxicity triggering receptor 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in decreased expression of NCR1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 1:69,614,744...69,622,594
Ensembl chr 1:69,616,601...69,660,558
|
|
G |
Ndufa1 |
NADH:ubiquinone oxidoreductase subunit A1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of NDUFA1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr X:116,424,223...116,427,875
Ensembl chr X:116,424,223...116,428,633
|
|
G |
Ndufa13 |
NADH:ubiquinone oxidoreductase subunit A13 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of NDUFA13 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr16:19,526,633...19,533,567
Ensembl chr16:19,526,565...19,535,726 Ensembl chr 7:19,526,565...19,535,726
|
|
G |
Ndufa3 |
NADH:ubiquinone oxidoreductase subunit A3 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of NDUFA3 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 1:65,597,567...65,600,197
Ensembl chr 1:65,597,578...65,600,235
|
|
G |
Ndufa5 |
NADH:ubiquinone oxidoreductase subunit A5 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of NDUFA5 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 4:52,997,327...53,005,685
Ensembl chr 4:52,995,546...53,005,598 Ensembl chr 5:52,995,546...53,005,598
|
|
G |
Ndufa6 |
NADH:ubiquinone oxidoreductase subunit A6 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of NDUFA6 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 7:113,866,382...113,870,239
Ensembl chr 7:113,866,382...113,870,239
|
|
G |
Ndufaf6 |
NADH:ubiquinone oxidoreductase complex assembly factor 6 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of NDUFAF6 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 5:24,147,712...24,171,981
Ensembl chr 5:24,147,735...24,171,951
|
|
G |
Ndufb1 |
NADH:ubiquinone oxidoreductase subunit B1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of NDUFB1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 6:121,115,649...121,124,055
|
|
G |
Ndufb10 |
NADH:ubiquinone oxidoreductase subunit B10 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of NDUFB10 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr10:13,749,273...13,751,434
Ensembl chr10:13,749,275...13,751,442
|
|
G |
Ndufb2 |
NADH:ubiquinone oxidoreductase subunit B2 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of NDUFB2 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 4:68,367,526...68,374,609
Ensembl chr15:46,536,062...46,536,851 Ensembl chr 4:46,536,062...46,536,851
|
|
G |
Ndufs5 |
NADH:ubiquinone oxidoreductase subunit S5 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of NDUFS5 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 5:135,974,029...135,979,705
Ensembl chr 5:135,974,034...135,979,603 Ensembl chr14:135,974,034...135,979,603 Ensembl chr 2:135,974,034...135,979,603
|
|
G |
Nedd1 |
NEDD1 gamma-tubulin ring complex targeting factor |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of NEDD1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 7:27,233,050...27,274,486
Ensembl chr 7:27,233,316...27,274,486
|
|
G |
Net1 |
neuroepithelial cell transforming 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in decreased expression of NET1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr17:66,341,251...66,370,445
Ensembl chr17:66,340,728...66,370,441
|
|
G |
Nf1 |
neurofibromin 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of NF1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr10:64,306,027...64,539,112
Ensembl chr10:64,306,301...64,536,658
|
|
G |
Nfatc2 |
nuclear factor of activated T-cells 2 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of NFATC2 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 3:157,195,970...157,328,640
Ensembl chr 3:157,198,872...157,328,325
|
|
G |
Nhlrc2 |
NHL repeat containing 2 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in decreased expression of NHLRC2 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 1:255,589,743...255,648,904
Ensembl chr 1:255,589,742...255,651,408
|
|
G |
Nhs |
NHS actin remodeling regulator |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of NHS mRNA |
CTD |
PMID:17183730 |
|
NCBI chr X:32,553,300...32,892,961
Ensembl chr X:32,552,026...32,889,992
|
|
G |
Nmd3 |
NMD3 ribosome export adaptor |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of NMD3 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 2:154,012,973...154,038,466
Ensembl chr 2:154,013,020...154,039,259
|
|
G |
Nme1 |
NME/NM23 nucleoside diphosphate kinase 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of NME1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr10:78,907,036...78,929,659
Ensembl chr10:78,906,083...78,916,408
|
|
G |
Nod1 |
nucleotide-binding oligomerization domain containing 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of NOD1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 4:84,060,871...84,111,668
Ensembl chr 4:84,060,880...84,111,404
|
|
G |
Nos1 |
nitric oxide synthase 1 |
increases expression |
EXP |
Hydralazine results in increased expression of NOS1 mRNA |
CTD |
PMID:7533141 |
|
NCBI chr12:38,615,111...38,795,492
Ensembl chr12:38,626,714...38,710,945
|
|
G |
Nova1 |
NOVA alternative splicing regulator 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of NOVA1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 6:63,780,105...63,905,567
Ensembl chr 6:63,783,489...63,906,289
|
|
G |
Npas3 |
neuronal PAS domain protein 3 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of NPAS3 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 6:70,702,773...71,527,928
Ensembl chr 6:70,703,170...71,524,884
|
|
G |
Npdc1 |
neural proliferation, differentiation and control, 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of NPDC1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 3:8,220,446...8,226,446
Ensembl chr 3:8,213,663...8,226,866
|
|
G |
Nphp4 |
nephrocystin 4 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of NPHP4 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 5:162,986,157...163,073,708
Ensembl chr 5:162,988,370...163,073,706
|
|
G |
Nppb |
natriuretic peptide B |
multiple interactions |
EXP |
Hydralazine inhibits the reaction [Nitric Oxide deficiency results in increased expression of NPPB mRNA] |
CTD |
PMID:16326922 |
|
NCBI chr 5:158,416,813...158,418,175
Ensembl chr 5:158,416,866...158,418,168
|
|
G |
Npr1 |
natriuretic peptide receptor 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of NPR1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 2:175,934,181...175,950,118
Ensembl chr 2:175,934,181...175,949,505
|
|
G |
Nr1h3 |
nuclear receptor subfamily 1, group H, member 3 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of NR1H3 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722
|
|
G |
Nr2c2 |
nuclear receptor subfamily 2, group C, member 2 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of NR2C2 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 4:124,610,216...124,666,813
Ensembl chr 4:124,608,960...124,661,902
|
|
G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of NR3C1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr18:31,271,681...31,393,320
Ensembl chr18:31,271,681...31,393,375
|
|
G |
Nrep |
neuronal regeneration related protein |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of NREP mRNA |
CTD |
PMID:17183730 |
|
NCBI chr18:25,017,069...25,046,593
Ensembl chr18:25,017,083...25,046,591
|
|
G |
Nrxn2 |
neurexin 2 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of NRXN2 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 1:203,726,420...203,842,301
Ensembl chr 1:203,735,753...203,842,297
|
|
G |
Nsdhl |
NAD(P) dependent steroid dehydrogenase-like |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of NSDHL mRNA |
CTD |
PMID:17183730 |
|
NCBI chr X:150,775,034...150,807,161
Ensembl chr X:150,775,080...150,807,142
|
|
G |
Nsfl1c |
NSFL1 cofactor |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of NSFL1C mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 3:139,978,306...140,002,876
Ensembl chr 3:139,978,301...140,002,870
|
|
G |
Nsun4 |
NOP2/Sun RNA methyltransferase 4 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of NSUN4 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 5:129,511,224...129,532,498
Ensembl chr 5:129,512,307...129,532,423 Ensembl chr 5:129,512,307...129,532,423
|
|
G |
Ntan1 |
N-terminal asparagine amidase |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of NTAN1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr10:2,111,090...2,126,119
|
|
G |
Ntsr2 |
neurotensin receptor 2 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in decreased expression of NTSR2 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 6:39,424,297...39,431,015
Ensembl chr 6:39,424,324...39,431,014
|
|
G |
Nudc |
nuclear distribution C, dynein complex regulator |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of NUDC mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 5:145,758,006...145,771,390
Ensembl chr 5:145,758,002...145,771,425
|
|
G |
Nudt7 |
nudix hydrolase 7 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in decreased expression of NUDT7 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr19:42,125,679...42,151,198
Ensembl chr19:42,125,711...42,151,081
|
|
G |
Numb |
NUMB, endocytic adaptor protein |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of NUMB mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 6:103,431,400...103,553,422
Ensembl chr 6:103,431,400...103,553,354
|
|
G |
Nup153 |
nucleoporin 153 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of NUP153 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr17:17,972,217...18,024,876
Ensembl chr17:17,972,217...18,024,876
|
|
G |
Nupr1 |
nuclear protein 1, transcriptional regulator |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of NUPR1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 1:181,213,292...181,215,327
Ensembl chr 1:181,213,368...181,215,281
|
|
G |
Nxph3 |
neurexophilin 3 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of NXPH3 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr10:80,456,283...80,459,949
Ensembl chr10:80,455,429...80,462,415
|
|
G |
Oaz1 |
ornithine decarboxylase antizyme 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of OAZ1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 7:8,883,855...8,886,315
Ensembl chr 7:8,883,851...8,886,310
|
|
G |
Obscn |
obscurin, cytoskeletal calmodulin and titin-interacting RhoGEF |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of OBSCN mRNA |
CTD |
PMID:17183730 |
|
NCBI chr10:43,774,113...43,919,718
Ensembl chr10:43,789,293...43,919,723
|
|
G |
Ociad2 |
OCIA domain containing 2 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of OCIAD2 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr14:34,873,668...34,889,276
Ensembl chr14:34,873,820...34,889,265
|
|
G |
Ofcc1 |
orofacial cleft 1 candidate 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in decreased expression of OFCC1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr17:24,506,919...24,813,225
Ensembl chr17:24,539,047...24,811,079
|
|
G |
Oga |
O-GlcNAcase |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of OGA mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 1:244,598,285...244,633,835
Ensembl chr 1:244,598,292...244,634,359
|
|
G |
Ogg1 |
8-oxoguanine DNA glycosylase |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of OGG1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 4:146,474,701...146,481,959
Ensembl chr 4:146,474,750...146,484,766
|
|
G |
Ogt |
O-linked N-acetylglucosamine (GlcNAc) transferase |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of OGT mRNA |
CTD |
PMID:17183730 |
|
NCBI chr X:66,771,278...66,816,148
Ensembl chr X:66,771,349...66,816,146
|
|
G |
Opa1 |
OPA1, mitochondrial dynamin like GTPase |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of OPA1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr11:71,108,100...71,185,170
Ensembl chr11:71,109,873...71,185,109
|
|
G |
Oprd1 |
opioid receptor, delta 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in decreased expression of OPRD1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 5:144,306,188...144,340,960
Ensembl chr 5:144,306,188...144,340,960
|
|
G |
Or9i1b |
olfactory receptor family 9 subfamily I member 1B |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of OR9I1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 1:211,096,191...211,097,141
Ensembl chr 1:211,090,402...211,097,815
|
|
G |
P2rx3 |
purinergic receptor P2X 3 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of P2RX3 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 3:70,080,850...70,124,664
Ensembl chr 3:70,080,851...70,125,178
|
|
G |
Pabpc1l2b |
poly(A) binding protein cytoplasmic 1 like 2B |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of PABPC1L2B mRNA |
CTD |
PMID:17183730 |
|
|
|
G |
Pafah1b3 |
platelet-activating factor acetylhydrolase 1b, catalytic subunit 3 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of PAFAH1B3 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 1:80,881,263...80,883,789
Ensembl chr 1:80,881,309...80,883,893
|
|
G |
Park7 |
Parkinsonism associated deglycase |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of PARK7 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 5:161,353,718...161,376,993
Ensembl chr 5:161,353,719...161,376,970
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of PARP1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Parp14 |
poly (ADP-ribose) polymerase family, member 14 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of PARP14 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr11:64,902,848...64,934,916
Ensembl chr11:64,902,785...64,934,916
|
|
G |
Pasd1 |
PAS domain containing repressor 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of PASD1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr X:149,617,933...149,639,214
Ensembl chr X:149,620,972...149,638,675
|
|
G |
Pbx2 |
PBX homeobox 2 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of PBX2 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr20:4,151,500...4,156,425
Ensembl chr20:4,151,500...4,156,425
|
|
G |
Pcbd1 |
pterin-4 alpha-carbinolamine dehydratase 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of PCBD1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr20:29,037,545...29,044,322
Ensembl chr20:28,953,864...29,044,292 Ensembl chr20:28,953,864...29,044,292
|
|
G |
Pccb |
propionyl-CoA carboxylase subunit beta |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of PCCB mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 8:101,591,218...101,641,213
Ensembl chr 8:101,590,737...101,641,234
|
|
G |
Pcdh15 |
protocadherin related 15 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of PCDH15 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr20:13,997,094...15,496,446
Ensembl chr20:13,963,565...15,494,719
|
|
G |
Pcna |
proliferating cell nuclear antigen |
multiple interactions |
EXP |
[troglitazone co-treated with [Hydrochlorothiazide co-treated with Hydralazine co-treated with Reserpine]] results in decreased expression of PCNA protein |
CTD |
PMID:11318962 |
|
NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
|
|
G |
Pdgfrb |
platelet derived growth factor receptor beta |
decreases expression |
EXP |
hydralazine decreases expression of Pdgfrb protein in liver |
RGD |
PMID:33315911 |
RGD:407420266 |
NCBI chr18:54,499,962...54,538,840
Ensembl chr18:54,499,964...54,538,843
|
|
G |
Pebp4 |
phosphatidylethanolamine binding protein 4 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of PEBP4 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr15:44,920,946...45,134,188
Ensembl chr15:44,921,886...45,134,191
|
|
G |
Pfkfb4 |
6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of PFKFB4 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 8:109,643,558...109,687,006
Ensembl chr 8:109,643,937...109,685,634
|
|
G |
Pfn1 |
profilin 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of PFN1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr10:55,365,263...55,367,968
Ensembl chr10:55,365,262...55,527,631
|
|
G |
Pgam2 |
phosphoglycerate mutase 2 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of PGAM2 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr14:80,681,796...80,683,907
Ensembl chr14:80,681,776...80,683,940
|
|
G |
Pgm1 |
phosphoglucomutase 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of PGM1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 5:114,595,298...114,654,728
Ensembl chr 5:114,595,293...114,654,728
|
|
G |
Phb1 |
prohibitin 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of PHB1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr10:80,605,268...80,618,043
Ensembl chr10:80,605,251...80,618,042
|
|
G |
Phc1 |
polyhomeotic homolog 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in decreased expression of PHC1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 4:155,510,274...155,532,636
Ensembl chr 4:155,510,274...155,533,959
|
|
G |
Phc2 |
polyhomeotic homolog 2 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of PHC2 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 5:141,000,604...141,099,268
Ensembl chr 5:141,050,842...141,099,268
|
|
G |
Phf24 |
PHD finger protein 24 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of PHF24 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 5:57,143,428...57,171,054
Ensembl chr 5:57,142,632...57,168,497
|
|
G |
Pigs |
phosphatidylinositol glycan anchor biosynthesis, class S |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of PIGS mRNA |
CTD |
PMID:17183730 |
|
NCBI chr10:63,222,611...63,237,190
Ensembl chr10:63,222,572...63,237,187
|
|
G |
Pip |
prolactin induced protein |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of PIP mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 4:70,787,627...70,791,921
Ensembl chr 4:70,787,627...70,791,921
|
|
G |
Plcg1 |
phospholipase C, gamma 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of PLCG1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 3:149,385,587...149,416,330
Ensembl chr 3:149,385,587...149,416,330
|
|
G |
Plrg1 |
pleiotropic regulator 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of PLRG1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 2:168,408,139...168,424,470
Ensembl chr 2:168,408,124...168,424,522
|
|
G |
Plxdc1 |
plexin domain containing 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of PLXDC1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr10:82,922,499...82,982,124
Ensembl chr10:82,922,508...82,982,130
|
|
G |
Pmm2 |
phosphomannomutase 2 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of PMM2 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr10:6,961,521...6,982,913
Ensembl chr10:6,961,709...6,983,098
|
|
G |
Pmvk |
phosphomevalonate kinase |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of PMVK mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 2:174,876,586...174,886,365
Ensembl chr 2:174,876,657...174,886,364
|
|
G |
Pole4 |
DNA polymerase epsilon 4, accessory subunit |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of POLE4 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 4:115,165,285...115,171,097
Ensembl chr 4:115,165,285...115,171,097
|
|
G |
Polr1has |
RNA polymerase I subunit H, antisense |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of POLR1HASP mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 9:16,098,624...16,099,790
Ensembl chr 9:16,098,624...16,099,790
|
|
G |
Polr2l |
RNA polymerase II, I and III subunit L |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of POLR2L mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 1:196,570,051...196,572,060
Ensembl chr19:8,335,702...8,335,905
|
|
G |
Pop5 |
POP5 homolog, ribonuclease P/MRP subunit |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of POP5 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr12:41,376,755...41,384,882
Ensembl chr12:41,376,755...41,381,336
|
|
G |
Ppil4 |
peptidylprolyl isomerase like 4 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of PPIL4 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 1:2,273,582...2,305,639
Ensembl chr 1:2,273,609...2,305,632
|
|
G |
Ppp1r12a |
protein phosphatase 1, regulatory subunit 12A |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of PPP1R12A mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 7:43,482,808...43,593,689
Ensembl chr 7:43,482,803...43,593,425
|
|
G |
Ppp1r9a |
protein phosphatase 1, regulatory subunit 9A |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of PPP1R9A mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 4:32,970,501...33,292,360
Ensembl chr 4:33,024,450...33,286,907
|
|
G |
Ppp2r1b |
protein phosphatase 2 scaffold subunit A beta |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of PPP2R1B mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 8:51,195,860...51,228,442
Ensembl chr 8:51,186,717...51,228,485
|
|
G |
Prb3 |
proline-rich protein BstNI subfamily 3 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of PRB3 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 4:165,564,424...165,569,229
Ensembl chr 4:165,564,424...165,569,227
|
|
G |
Prkcsh |
PRKCSH beta subunit of glucosidase II |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of PRKCSH mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 8:20,534,787...20,546,493
Ensembl chr 8:20,534,880...20,546,492
|
|
G |
Prkg1 |
protein kinase cGMP-dependent 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of PRKG1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 1:228,409,605...229,638,794
Ensembl chr 1:228,408,947...229,639,080
|
|
G |
Prom2 |
prominin 2 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of PROM2 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 3:114,747,654...114,761,787
Ensembl chr 3:114,747,654...114,761,787
|
|
G |
Prpf18 |
pre-mRNA processing factor 18 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of PRPF18 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr17:73,630,560...73,661,210
Ensembl chr17:73,630,571...73,690,979
|
|
G |
Prr13 |
proline rich 13 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of PRR13 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 7:133,592,511...133,595,817
Ensembl chr 7:133,592,490...133,601,005
|
|
G |
Prtfdc1 |
phosphoribosyl transferase domain containing 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of PRTFDC1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr17:83,549,608...83,654,517
Ensembl chr17:83,548,803...83,655,179
|
|
G |
Psd3 |
pleckstrin and Sec7 domain containing 3 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of PSD3 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr16:21,465,643...22,035,846
Ensembl chr16:21,465,639...22,034,547
|
|
G |
Psma2 |
proteasome 20S subunit alpha 2 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of PSMA2 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr17:50,554,536...50,564,923
Ensembl chr17:50,551,924...50,564,938
|
|
G |
Psma4 |
proteasome 20S subunit alpha 4 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of PSMA4 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 8:55,340,431...55,347,893
Ensembl chr 8:55,340,386...55,347,890
|
|
G |
Psmb1 |
proteasome 20S subunit beta 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of PSMB1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 1:56,442,432...56,463,544
Ensembl chr 1:56,420,618...56,463,560
|
|
G |
Psmb2 |
proteasome 20S subunit beta 2 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of PSMB2 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 5:138,970,564...139,002,715
Ensembl chr 5:138,970,533...139,021,137
|
|
G |
Psmb3 |
proteasome 20S subunit beta 3 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of PSMB3 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr10:82,697,425...82,704,521
Ensembl chr10:82,697,425...82,704,521
|
|
G |
Psmb6 |
proteasome 20S subunit beta 6 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of PSMB6 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr10:55,239,256...55,241,586
Ensembl chr10:55,239,241...55,241,586
|
|
G |
Psmb9 |
proteasome 20S subunit beta 9 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of PSMB9 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr20:4,667,044...4,672,512
Ensembl chr20:4,666,046...4,672,512
|
|
G |
Psmc6 |
proteasome 26S subunit, ATPase 6 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of PSMC6 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr15:18,542,585...18,564,057
Ensembl chr15:18,542,563...18,564,055
|
|
G |
Psmd1 |
proteasome 26S subunit, non-ATPase 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of PSMD1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 9:86,709,714...86,785,213
Ensembl chr 9:86,709,947...86,785,211
|
|
G |
Psmd3 |
proteasome 26S subunit, non-ATPase 3 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in decreased expression of PSMD3 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr10:83,643,473...83,655,620
Ensembl chr10:83,643,647...83,655,618
|
|
G |
Psmd4 |
proteasome 26S subunit ubiquitin receptor, non-ATPase 4 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of PSMD4 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 2:182,598,934...182,608,250
Ensembl chr 2:182,598,934...182,608,194
|
|
G |
Psmd8 |
proteasome 26S subunit, non-ATPase 8 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of PSMD8 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 1:84,474,377...84,481,209
Ensembl chr 1:84,474,378...84,481,209
|
|
G |
Psmg3 |
proteasome assembly chaperone 3 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of PSMG3 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr12:14,809,440...14,812,357
Ensembl chr12:14,809,450...14,812,342
|
|
G |
Ptk2b |
protein tyrosine kinase 2 beta |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of PTK2B mRNA |
CTD |
PMID:17183730 |
|
NCBI chr15:40,360,722...40,481,235
Ensembl chr15:40,360,723...40,481,282
|
|
G |
Ptma |
prothymosin alpha |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of PTMA mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 9:87,176,251...87,180,333
Ensembl chr 9:87,176,230...87,180,333
|
|
G |
Ptprj |
protein tyrosine phosphatase, receptor type, J |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of PTPRJ mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 3:76,405,917...76,561,842
Ensembl chr 3:76,405,927...76,562,260
|
|
G |
Puf60 |
poly-U binding splicing factor 60 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of PUF60 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 7:107,782,799...107,793,759
Ensembl chr 7:107,782,770...107,794,531
|
|
G |
Pum1 |
pumilio RNA-binding family member 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of PUM1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 5:142,836,933...142,954,331
Ensembl chr 5:142,837,127...142,954,039
|
|
G |
Pycard |
PYD and CARD domain containing |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of PYCARD mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 1:182,601,657...182,603,013
Ensembl chr 1:182,601,174...182,602,955
|
|
G |
Pycr3 |
pyrroline-5-carboxylate reductase 3 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of PYCR3 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 7:107,603,543...107,608,831
Ensembl chr 7:107,581,930...107,608,799
|
|
G |
Rab13 |
RAB13, member RAS oncogene family |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of RAB13 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 2:175,674,894...175,680,043
Ensembl chr 2:175,675,005...175,680,036
|
|
G |
Rab1a |
RAB1A, member RAS oncogene family |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of RAB1A mRNA |
CTD |
PMID:17183730 |
|
NCBI chr14:94,422,219...94,448,799
Ensembl chr14:94,415,275...94,448,248
|
|
G |
Rab30 |
RAB30, member RAS oncogene family |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of RAB30 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 1:146,803,719...146,898,369
Ensembl chr 1:146,803,714...146,892,181
|
|
G |
Rab3a |
RAB3A, member RAS oncogene family |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of RAB3A mRNA |
CTD |
PMID:17183730 |
|
NCBI chr16:18,684,185...18,688,297
Ensembl chr16:18,684,188...18,688,336
|
|
G |
Rab3d |
RAB3D, member RAS oncogene family |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of RAB3D mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 8:20,438,622...20,449,269
Ensembl chr 8:20,439,294...20,449,185
|
|
G |
Rab6a |
RAB6A, member RAS oncogene family |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of RAB6A mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 1:154,957,870...155,008,922
Ensembl chr 1:154,958,189...154,996,715
|
|
G |
Rabep2 |
rabaptin, RAB GTPase binding effector protein 2 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of RABEP2 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 1:181,010,305...181,026,651
Ensembl chr 1:181,010,305...181,026,648
|
|
G |
Rabgef1 |
RAB guanine nucleotide exchange factor 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of RABGEF1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr12:26,459,190...26,503,790
Ensembl chr12:26,460,175...26,503,744
|
|
G |
Rad21 |
RAD21 cohesin complex component |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of RAD21 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 7:83,287,867...83,314,810
Ensembl chr 7:83,287,870...83,314,817
|
|
G |
Ralgds |
ral guanine nucleotide dissociation stimulator |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of RALGDS mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 3:11,839,686...11,880,059
Ensembl chr 3:11,839,416...11,880,059
|
|
G |
Ralgps1 |
Ral GEF with PH domain and SH3 binding motif 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of RALGPS1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 3:16,433,323...16,670,276
Ensembl chr 3:16,433,742...16,669,972
|
|
G |
Ramp2 |
receptor activity modifying protein 2 |
multiple interactions |
EXP |
Hydralazine inhibits the reaction [Nitric Oxide deficiency results in increased expression of RAMP2 protein] |
CTD |
PMID:16326922 |
|
NCBI chr10:86,187,366...86,190,692
Ensembl chr10:86,188,812...86,231,829
|
|
G |
Ramp3 |
receptor activity modifying protein 3 |
multiple interactions |
EXP |
Hydralazine inhibits the reaction [Nitric Oxide deficiency results in increased expression of RAMP3 protein] |
CTD |
PMID:16326922 |
|
NCBI chr14:81,527,404...81,544,905
Ensembl chr14:81,527,385...81,544,902
|
|
G |
Rap1a |
RAP1A, member of RAS oncogene family |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of RAP1A mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 2:193,208,631...193,286,513
Ensembl chr 2:193,208,635...193,286,501
|
|
G |
Rarb |
retinoic acid receptor, beta |
decreases methylation |
ISO |
Hydralazine results in decreased methylation of RARB promoter |
CTD |
PMID:15862127 |
|
NCBI chr15:8,700,533...9,051,288
Ensembl chr15:8,406,492...9,051,288
|
|
G |
Rbl1 |
RB transcriptional corepressor like 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of RBL1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 3:145,806,160...145,869,434
Ensembl chr 3:145,807,095...145,869,330
|
|
G |
Rbm22 |
RNA binding motif protein 22 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of RBM22 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr18:54,013,374...54,024,182
Ensembl chr18:54,013,351...54,024,569
|
|
G |
Rbm4 |
RNA binding motif protein 4 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of RBM4 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 1:202,078,442...202,087,506
Ensembl chr 1:202,085,279...202,105,380
|
|
G |
Rcl1 |
RNA terminal phosphate cyclase-like 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of RCL1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 1:226,824,561...226,869,046
Ensembl chr 1:226,824,534...226,902,315
|
|
G |
Reep4 |
receptor accessory protein 4 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of REEP4 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr15:45,620,317...45,623,524
Ensembl chr15:45,619,941...45,623,526
|
|
G |
Reg1a |
regenerating family member 1 alpha |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in decreased expression of REG1A mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 4:110,892,451...110,895,115
Ensembl chr 4:110,892,453...110,895,570
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
Hydralazine inhibits the reaction [Acrolein promotes the reaction [RELA protein binds to FASLG promoter]]; Hydralazine inhibits the reaction [Acrolein promotes the reaction [Zidovudine promotes the reaction [RELA protein binds to FASLG promoter]]]; Hydralazine inhibits the reaction [Zidovudine promotes the reaction [Acrolein promotes the reaction [RELA protein binds to FASLG promoter]]]; Hydralazine inhibits the reaction [Zidovudine promotes the reaction [RELA protein binds to FASLG promoter]] |
CTD |
PMID:27238871 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Ren |
renin |
multiple interactions increases activity increases expression |
ISO EXP |
Alprenolol inhibits the reaction [Hydralazine results in increased expression of REN protein] Hydralazine results in increased activity of REN protein |
CTD |
PMID:231700 PMID:923630 PMID:2203898 PMID:2953239 PMID:3154321 |
|
NCBI chr13:44,796,260...44,807,491
Ensembl chr13:44,796,091...44,807,489
|
|
G |
Rer1 |
retention in endoplasmic reticulum sorting receptor 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of RER1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 5:165,634,567...165,646,643
Ensembl chr 5:165,634,300...165,646,750
|
|
G |
Rfx1 |
regulatory factor X1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of RFX1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr19:24,061,336...24,092,044
Ensembl chr19:24,061,336...24,092,044
|
|
G |
Rgs7bp |
regulator of G-protein signaling 7 binding protein |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of RGS7BP mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 2:36,133,944...36,231,505
Ensembl chr 2:36,139,201...36,231,505
|
|
G |
Rgs9 |
regulator of G-protein signaling 9 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of RGS9 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr10:94,195,265...94,270,892
Ensembl chr10:94,197,054...94,270,892
|
|
G |
Rgs9bp |
regulator of G protein signaling 9 binding protein |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of RGS9BP mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 1:88,249,438...88,250,151
Ensembl chr 1:88,249,438...88,250,151
|
|
G |
Rin3 |
Ras and Rab interactor 3 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of RIN3 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 6:121,431,776...121,540,956
Ensembl chr 6:121,431,339...121,540,957
|
|
G |
Rinl |
Ras and Rab interactor-like |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of RINL mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 1:84,077,011...84,088,590
Ensembl chr 1:84,077,265...84,088,330
|
|
G |
Ripk1 |
receptor interacting serine/threonine kinase 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of RIPK1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr17:30,839,639...30,871,824
Ensembl chr17:30,839,650...30,871,824
|
|
G |
Ripply1 |
ripply transcriptional repressor 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of RIPPLY1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr X:103,436,731...103,440,904
Ensembl chr X:103,436,729...103,443,349
|
|
G |
Rmnd5b |
required for meiotic nuclear division 5 homolog B |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of RMND5B mRNA |
CTD |
PMID:17183730 |
|
NCBI chr10:35,881,250...35,892,322
Ensembl chr10:35,881,268...35,892,265
|
|
G |
Rnf152 |
ring finger protein 152 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of RNF152 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr13:21,324,039...21,403,405
Ensembl chr13:21,323,824...21,403,113
|
|
G |
Rnf187 |
ring finger protein 187 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of RNF187 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr10:43,709,493...43,715,392
Ensembl chr10:43,702,357...43,716,157
|
|
G |
Robo2 |
roundabout guidance receptor 2 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of ROBO2 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr11:12,528,949...14,096,726
Ensembl chr11:12,528,951...13,041,536
|
|
G |
Romo1 |
reactive oxygen species modulator 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of ROMO1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 3:144,659,709...144,661,310
Ensembl chr 3:144,659,826...144,661,310
|
|
G |
Rpl10a |
ribosomal protein L10A |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of RPL10A mRNA |
CTD |
PMID:17183730 |
|
NCBI chr20:6,388,800...6,391,358
Ensembl chr20:6,385,823...6,391,357 Ensembl chr 9:6,385,823...6,391,357
|
|
G |
Rpl13 |
ribosomal protein L13 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of RPL13 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr19:51,153,990...51,156,541
Ensembl chr19:51,153,924...51,163,014
|
|
G |
Rpl17 |
ribosomal protein L17 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of RPL17 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr18:68,581,141...68,584,253
Ensembl chr18:68,581,098...68,584,253 Ensembl chr 3:68,581,098...68,584,253
|
|
G |
Rpl18a |
ribosomal protein L18A |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of RPL18A mRNA |
CTD |
PMID:17183730 |
|
NCBI chr16:18,542,555...18,544,578
Ensembl chr16:18,542,566...18,545,546 Ensembl chr 1:18,542,566...18,545,546
|
|
G |
Rpl23a |
ribosomal protein L23A |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of RPL23A mRNA |
CTD |
PMID:17183730 |
|
NCBI chr10:63,076,660...63,079,346
Ensembl chr10:63,076,066...63,079,346 Ensembl chr15:63,076,066...63,079,346
|
|
G |
Rpl24 |
ribosomal protein L24 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of RPL24 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr11:44,653,937...44,659,346
Ensembl chr11:44,653,937...44,659,370
|
|
G |
Rpl26 |
ribosomal protein L26 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of RPL26 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr10:53,610,836...53,613,966
Ensembl chr10:53,610,421...53,613,966
|
|
G |
Rpl27 |
ribosomal protein L27 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of RPL27 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr10:86,375,511...86,379,210
Ensembl chr10:86,375,454...86,379,193
|
|
G |
Rpl31 |
ribosomal protein L31 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of RPL31 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 9:41,647,397...41,651,441
Ensembl chr 9:41,647,426...41,662,129 Ensembl chr 8:41,647,426...41,662,129
|
|
G |
Rpl34 |
ribosomal protein L34 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of RPL34 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 2:219,284,373...219,288,108
Ensembl chr 2:219,284,382...219,288,111 Ensembl chr17:219,284,382...219,288,111
|
|
G |
Rpl36 |
ribosomal protein L36 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of RPL36 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 9:1,441,986...1,447,397
Ensembl chr 6:98,809,534...98,809,897 Ensembl chr 5:98,809,534...98,809,897
|
|
G |
Rpl37a |
ribosomal protein L37A |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of RPL37A mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 9:74,298,843...74,300,926
|
|
G |
Rpl39 |
ribosomal protein L39 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of RPL39 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr X:116,327,216...116,330,211
Ensembl chr18:6,326,330...6,326,692 Ensembl chr X:6,326,330...6,326,692 Ensembl chr X:6,326,330...6,326,692 Ensembl chr15:6,326,330...6,326,692 Ensembl chr20:6,326,330...6,326,692 Ensembl chr 7:6,326,330...6,326,692
|
|
G |
Rpl41 |
ribosomal protein L41 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of RPL41 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 7:977,885...978,965
|
|
G |
Rpl7 |
ribosomal protein L7 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of RPL7 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 5:3,217,184...3,220,192
|
|
G |
Rplp1 |
ribosomal protein lateral stalk subunit P1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of RPLP1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 8:62,394,008...62,395,341
Ensembl chr 8:62,393,177...62,395,339
|
|
G |
Rpp21 |
ribonuclease P/MRP subunit p21 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of RPP21 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr20:2,018,170...2,020,100
Ensembl chr20:2,018,147...2,020,106
|
|
G |
Rps11 |
ribosomal protein S11 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of RPS11 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 1:95,605,690...95,607,798
Ensembl chr 1:95,605,692...95,607,874
|
|
G |
Rps12 |
ribosomal protein S12 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of RPS12 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 1:21,680,854...21,683,010
Ensembl chr 1:21,680,852...21,683,014
|
|
G |
Rps19bp1 |
ribosomal protein S19 binding protein 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of RPS19BP1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 7:111,809,354...111,812,741
Ensembl chr 7:111,809,355...111,812,757
|
|
G |
Rps2 |
ribosomal protein S2 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of RPS2 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr10:13,747,316...13,749,165
Ensembl chr10:13,747,301...13,749,163
|
|
G |
Rps27 |
ribosomal protein S27 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of RPS27 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 2:175,665,858...175,666,963
Ensembl chr 2:175,665,853...175,666,964 Ensembl chr12:175,665,853...175,666,964
|
|
G |
Rps27a |
ribosomal protein S27a |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of RPS27A mRNA |
CTD |
PMID:17183730 |
|
NCBI chr14:103,285,734...103,288,011
Ensembl chr14:103,285,734...103,288,011 Ensembl chr 5:103,285,734...103,288,011 Ensembl chr 5:103,285,734...103,288,011
|
|
G |
Rps6ka5 |
ribosomal protein S6 kinase A5 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of RPS6KA5 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 6:119,828,823...120,006,190
Ensembl chr 6:119,828,846...120,006,224
|
|
G |
Rps9 |
ribosomal protein S9 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of RPS9 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 1:65,511,723...65,515,076
Ensembl chr 1:65,511,723...65,515,123
|
|
G |
Rspo4 |
R-spondin 4 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of RSPO4 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 3:140,357,256...140,391,780
Ensembl chr 3:140,357,424...140,388,254
|
|
G |
Rsrp1 |
arginine and serine rich protein 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of RSRP1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 5:147,147,774...147,151,523
Ensembl chr 5:147,147,784...147,151,523
|
|
G |
RT1-CE16 |
RT1 class I, locus CE16 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of HLA-A mRNA |
CTD |
PMID:17183730 |
|
NCBI chr20:3,257,109...3,260,747
Ensembl chr20:3,257,123...3,279,563
|
|
G |
RT1-DOb |
RT1 class II, locus DOb |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of HLA-DOB mRNA |
CTD |
PMID:17183730 |
|
NCBI chr20:4,619,418...4,625,627
Ensembl chr20:4,619,816...4,625,667
|
|
G |
Rtn4rl1 |
reticulon 4 receptor-like 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of RTN4RL1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr10:60,043,246...60,116,977
Ensembl chr10:60,043,002...60,116,978
|
|
G |
Rwdd1 |
RWD domain containing 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of RWDD1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr20:25,949,723...25,967,147
Ensembl chr20:25,941,966...25,967,193
|
|
G |
Rxrg |
retinoid X receptor gamma |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of RXRG mRNA |
CTD |
PMID:17183730 |
|
NCBI chr13:79,743,430...79,785,173
Ensembl chr13:79,743,563...79,785,167
|
|
G |
S100a6 |
S100 calcium binding protein A6 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of S100A6 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 2:176,100,619...176,102,181
Ensembl chr 2:176,100,899...176,102,180
|
|
G |
S100a8 |
S100 calcium binding protein A8 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in decreased expression of S100A8 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 2:176,166,517...176,167,645
Ensembl chr 2:176,167,124...176,167,643
|
|
G |
S100pbp |
S100P binding protein |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of S100PBP mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 5:141,494,352...141,535,752
Ensembl chr 5:141,494,353...141,535,525
|
|
G |
Samd4a |
sterile alpha motif domain containing 4A |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of SAMD4A mRNA |
CTD |
PMID:17183730 |
|
NCBI chr15:20,135,994...20,352,131
Ensembl chr15:20,134,377...20,348,380
|
|
G |
Samm50 |
SAMM50 sorting and assembly machinery component |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of SAMM50 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 7:115,317,472...115,341,682
Ensembl chr 7:115,317,404...115,341,682
|
|
G |
Saraf |
store-operated calcium entry-associated regulatory factor |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of SARAF mRNA |
CTD |
PMID:17183730 |
|
NCBI chr16:58,017,231...58,035,481
Ensembl chr16:58,017,231...58,035,545
|
|
G |
Scap |
SREBF chaperone |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of SCAP mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 8:110,306,026...110,360,677
Ensembl chr 8:110,306,031...110,360,666
|
|
G |
Scarf1 |
scavenger receptor class F, member 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of SCARF1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr10:60,359,213...60,371,516
Ensembl chr10:60,359,197...60,371,516
|
|
G |
Scml1 |
Scm polycomb group protein like 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in decreased expression of SCML1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr X:32,893,100...32,912,686
Ensembl chr X:32,894,327...32,911,366
|
|
G |
Scnn1b |
sodium channel epithelial 1 subunit beta |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of SCNN1B mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 1:176,430,063...176,484,451
Ensembl chr 1:176,430,103...176,484,451
|
|
G |
Scrn2 |
secernin 2 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of SCRN2 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr10:82,016,604...82,020,676
Ensembl chr10:82,016,649...82,020,675
|
|
G |
Sdf2l1 |
stromal cell-derived factor 2-like 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of SDF2L1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr11:83,872,659...83,874,902
Ensembl chr11:83,872,659...83,874,902
|
|
G |
Sdhaf3 |
succinate dehydrogenase complex assembly factor 3 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of SDHAF3 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 4:35,100,533...35,160,740
Ensembl chr 4:35,100,506...35,160,749
|
|
G |
Sec11c |
SEC11 homolog C, signal peptidase complex subunit |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of SEC11C mRNA |
CTD |
PMID:17183730 |
|
NCBI chr18:59,320,932...59,337,272
Ensembl chr18:59,320,884...59,337,364
|
|
G |
Sec31a |
SEC31 homolog A, COPII coat complex component |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of SEC31A mRNA |
CTD |
PMID:17183730 |
|
NCBI chr14:9,214,324...9,269,281
Ensembl chr14:9,214,349...9,269,273
|
|
G |
Selenow |
selenoprotein W |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of SELENOW mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 1:76,599,441...76,604,514
Ensembl chr 1:76,598,779...76,604,724 Ensembl chr 1:76,598,779...76,604,724
|
|
G |
Selplg |
selectin P ligand |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in decreased expression of SELPLG mRNA |
CTD |
PMID:17183730 |
|
NCBI chr12:42,796,690...42,809,908
Ensembl chr12:42,796,580...42,812,585
|
|
G |
Sema4a |
semaphorin 4A |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of SEMA4A mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 2:173,896,432...173,917,903
Ensembl chr 2:173,896,439...173,914,442
|
|
G |
Septin2 |
septin 2 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of SEPTIN2 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 9:94,018,141...94,051,386
Ensembl chr 9:94,018,208...94,051,386
|
|
G |
Serp2 |
stress-associated endoplasmic reticulum protein family member 2 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of SERP2 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr15:51,879,882...51,903,958
Ensembl chr15:51,879,877...51,904,785
|
|
G |
Serpine1 |
serpin family E member 1 |
multiple interactions decreases expression |
EXP |
[troglitazone co-treated with [Hydrochlorothiazide co-treated with Hydralazine co-treated with Reserpine]] results in decreased expression of SERPINE1 mRNA; [troglitazone co-treated with [Hydrochlorothiazide co-treated with Hydralazine co-treated with Reserpine]] results in decreased expression of SERPINE1 protein Hydralazine results in decreased expression of SERPINE1 mRNA |
CTD |
PMID:11318962 PMID:23415681 |
|
NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657
|
|
G |
Serping1 |
serpin family G member 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of SERPING1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 3:69,842,726...69,852,583
Ensembl chr 3:69,842,739...69,852,034
|
|
G |
Sertad2 |
SERTA domain containing 2 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of SERTAD2 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr14:94,733,637...94,838,200
Ensembl chr14:94,733,579...94,838,313
|
|
G |
Sf1 |
splicing factor 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of SF1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 1:203,670,016...203,683,432
Ensembl chr 1:203,670,018...203,684,330
|
|
G |
Sf3b6 |
splicing factor 3B, subunit 6 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of SF3B6 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 6:27,826,044...27,835,086
Ensembl chr 6:27,826,029...27,835,156
|
|
G |
Shank2 |
SH3 and multiple ankyrin repeat domains 2 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of SHANK2 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 1:199,146,210...199,590,962
Ensembl chr 1:199,169,429...199,589,394
|
|
G |
Shisa2 |
shisa family member 2 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of SHISA2 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr15:33,806,715...33,811,013
Ensembl chr15:33,805,958...33,811,013
|
|
G |
Shoc1 |
shortage in chiasmata 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of SHOC1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 5:73,864,423...73,956,487
Ensembl chr 5:73,866,334...73,956,444
|
|
G |
Shox2 |
SHOX homeobox 2 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in decreased expression of SHOX2 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 2:151,217,049...151,227,180
Ensembl chr 2:151,217,552...151,227,143
|
|
G |
Sidt2 |
SID1 transmembrane family, member 2 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of SIDT2 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 8:46,232,379...46,248,913
Ensembl chr 8:46,232,383...46,248,700
|
|
G |
Sipa1l1 |
signal-induced proliferation-associated 1 like 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of SIPA1L1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 6:101,839,351...102,118,408
Ensembl chr 6:101,839,404...102,116,950
|
|
G |
Ski |
Ski proto-oncogene |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in decreased expression of SKI mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 5:165,713,525...165,782,134
Ensembl chr 5:165,714,093...165,782,733
|
|
G |
Slc12a3 |
solute carrier family 12 member 3 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of SLC12A3 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr19:10,630,651...10,679,250
Ensembl chr19:10,631,393...10,669,091
|
|
G |
Slc16a2 |
solute carrier family 16 member 2 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of SLC16A2 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr X:68,725,365...68,848,572
Ensembl chr X:68,723,261...68,848,771
|
|
G |
Slc17a9 |
solute carrier family 17 member 9 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of SLC17A9 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 3:167,839,246...167,857,462
Ensembl chr 3:167,839,385...167,855,985
|
|
G |
Slc19a2 |
solute carrier family 19 member 2 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of SLC19A2 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr13:76,601,975...76,616,175
Ensembl chr13:76,601,900...76,616,172
|
|
G |
Slc22a16 |
solute carrier family 22 member 16 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of SLC22A16 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr20:43,972,808...44,068,447
Ensembl chr20:43,972,836...44,065,019
|
|
G |
Slc22a17 |
solute carrier family 22, member 17 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of SLC22A17 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr15:28,382,285...28,389,435
Ensembl chr15:28,382,292...28,388,799
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
multiple interactions |
ISO |
Hydralazine inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:21599003 |
|
NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
|
|
G |
Slc23a3 |
solute carrier family 23, member 3 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of SLC23A3 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 9:76,622,621...76,633,188
Ensembl chr 9:76,622,800...76,631,366
|
|
G |
Slc25a13 |
solute carrier family 25 member 13 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of SLC25A13 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 4:34,179,224...34,361,912
Ensembl chr 4:34,179,224...34,361,902
|
|
G |
Slc25a5 |
solute carrier family 25 member 5 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of SLC25A5 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr X:116,031,896...116,034,963
Ensembl chr X:116,031,803...116,034,967
|
|
G |
Slc2a9 |
solute carrier family 2 member 9 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of SLC2A9 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr14:72,328,334...72,461,981
Ensembl chr14:72,328,320...72,461,981
|
|
G |
Slc30a2 |
solute carrier family 30 member 2 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of SLC30A2 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 5:146,559,733...146,571,957
Ensembl chr 5:146,559,733...146,571,956
|
|
G |
Slc35c1 |
solute carrier family 35 member C1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of SLC35C1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 3:78,421,925...78,429,603
Ensembl chr 3:78,421,933...78,428,520
|
|
G |
Slc3a2 |
solute carrier family 3 member 2 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of SLC3A2 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 1:205,604,468...205,618,931
Ensembl chr 1:205,604,468...205,618,931
|
|
G |
Slc6a13 |
solute carrier family 6 member 13 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of SLC6A13 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 4:154,539,246...154,577,784
Ensembl chr 4:154,540,468...154,576,152
|
|
G |
Slc6a2 |
solute carrier family 6 member 2 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of SLC6A2 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr19:14,010,292...14,055,317
Ensembl chr19:14,010,386...14,050,357
|
|
G |
Slc8b1 |
solute carrier family 8 member B1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of SLC8B1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr12:36,029,759...36,053,087
Ensembl chr12:36,029,760...36,053,031
|
|
G |
Slirp |
SRA stem-loop interacting RNA binding protein |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of SLIRP mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 6:107,088,760...107,097,791
Ensembl chr 6:107,088,403...107,097,791
|
|
G |
Smarcc1 |
SWI/SNF related BAF chromatin remodeling complex subunit C1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of SMARCC1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 8:110,111,097...110,214,734
Ensembl chr 8:110,111,122...110,214,720
|
|
G |
Smo |
smoothened, frizzled class receptor |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of SMO mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 4:58,343,626...58,373,823
Ensembl chr 4:58,343,529...58,373,829
|
|
G |
Smurf2 |
SMAD specific E3 ubiquitin protein ligase 2 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of SMURF2 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr10:91,761,798...91,862,485
Ensembl chr10:91,761,807...91,862,488
|
|
G |
Snai3 |
snail family transcriptional repressor 3 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of SNAI3 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr19:50,516,771...50,529,295
Ensembl chr19:50,516,771...50,523,486
|
|
G |
Snf8 |
SNF8 subunit of ESCRT-II |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of SNF8 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr10:80,984,337...80,996,724
Ensembl chr10:80,984,363...80,996,734
|
|
G |
Snrnp70 |
small nuclear ribonucleoprotein U1 subunit 70 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of SNRNP70 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 1:95,856,038...95,876,434
Ensembl chr 1:95,856,036...95,876,392
|
|
G |
Snrpb |
small nuclear ribonucleoprotein polypeptides B and B1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of SNRPB mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 3:117,369,816...117,379,344
Ensembl chr 3:117,370,100...117,379,339
|
|
G |
Snrpb2 |
small nuclear ribonucleoprotein polypeptide B2 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of SNRPB2 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 3:130,399,239...130,408,821
Ensembl chr 3:130,399,248...130,408,812
|
|
G |
Snrpd2 |
small nuclear ribonucleoprotein D2 polypeptide |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of SNRPD2 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 1:78,798,377...78,801,227
Ensembl chr 1:78,798,377...78,803,351 Ensembl chr20:78,798,377...78,803,351
|
|
G |
Snrpg |
small nuclear ribonucleoprotein polypeptide G |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of SNRPG mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 4:118,812,278...118,819,827
Ensembl chr 4:118,812,252...118,819,826 Ensembl chr X:118,812,252...118,819,826
|
|
G |
Snu13 |
small nuclear ribonucleoprotein 13 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of SNU13 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 7:113,565,293...113,570,887
Ensembl chr 7:113,565,295...113,570,872 Ensembl chr 1:113,565,295...113,570,872
|
|
G |
Sox1 |
SRY-box transcription factor 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of SOX1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr16:77,135,577...77,139,592
Ensembl chr16:77,137,584...77,138,762
|
|
G |
Sox9 |
SRY-box transcription factor 9 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of SOX9 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr10:97,806,485...97,811,994
Ensembl chr10:97,806,485...97,811,994
|
|
G |
Spdef |
SAM pointed domain containing ets transcription factor |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of SPDEF mRNA |
CTD |
PMID:17183730 |
|
NCBI chr20:5,771,440...5,785,893
Ensembl chr20:5,771,441...5,785,893
|
|
G |
Spint1 |
serine peptidase inhibitor, Kunitz type 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of SPINT1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 3:106,231,082...106,244,121
Ensembl chr 3:106,231,444...106,244,119
|
|
G |
Sprr1a |
small proline-rich protein 1A |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in decreased expression of SPRR1A mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 2:178,055,096...178,057,012
Ensembl chr 2:178,055,096...178,057,063
|
|
G |
Sprr1b |
small proline-rich protein 1B |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in decreased expression of SPRR1B mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 2:178,008,844...178,010,742
Ensembl chr 2:178,009,130...178,009,567
|
|
G |
Spsb2 |
splA/ryanodine receptor domain and SOCS box containing 2 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of SPSB2 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 4:157,613,404...157,615,293
Ensembl chr 4:157,613,401...157,615,284
|
|
G |
Srp72 |
signal recognition particle 72 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of SRP72 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr14:31,168,175...31,195,717
Ensembl chr14:31,168,293...31,195,729
|
|
G |
Srp9 |
signal recognition particle 9 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of SRP9 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr13:93,832,580...93,840,720
Ensembl chr13:93,832,580...93,840,720
|
|
G |
Srpk3 |
SRSF protein kinase 3 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of SRPK3 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr X:151,510,452...151,515,208
Ensembl chr X:151,510,539...151,515,198
|
|
G |
Srxn1 |
sulfiredoxin 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of SRXN1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 3:140,604,490...140,610,050
Ensembl chr 3:140,599,608...140,628,448
|
|
G |
Ssbp4 |
single stranded DNA binding protein 4 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of SSBP4 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr16:18,828,014...18,838,941
Ensembl chr16:18,828,054...18,838,947
|
|
G |
Sspn |
sarcospan |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of SSPN mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 4:178,890,030...178,946,267
Ensembl chr 4:178,897,147...178,931,554
|
|
G |
Ssr1 |
signal sequence receptor subunit 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of SSR1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr17:26,833,720...26,861,821
Ensembl chr17:26,833,741...26,861,821
|
|
G |
St8sia2 |
ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 2 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of ST8SIA2 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 1:127,762,573...127,838,017
Ensembl chr 1:127,762,573...127,838,091
|
|
G |
Stab2 |
stabilin 2 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of STAB2 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 7:21,249,426...21,433,051
Ensembl chr 7:21,249,391...21,434,042
|
|
G |
Stag1 |
STAG1 cohesin complex component |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of STAG1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 8:101,179,039...101,564,684
Ensembl chr 8:101,179,039...101,564,677
|
|
G |
Steap2 |
STEAP2 metalloreductase |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in decreased expression of STEAP2 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 4:28,347,769...28,368,177
Ensembl chr 4:28,348,362...28,375,791
|
|
G |
Stk38 |
serine/threonine kinase 38 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of STK38 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr20:7,034,245...7,067,803
Ensembl chr20:7,034,242...7,068,198
|
|
G |
Stx11 |
syntaxin 11 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of STX11 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 1:7,293,427...7,320,060
Ensembl chr 1:7,289,976...7,320,164
|
|
G |
Stx5 |
syntaxin 5 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of STX5 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 1:205,637,401...205,653,563
Ensembl chr 1:205,637,413...205,653,563
|
|
G |
Styx |
serine/threonine/tyrosine interacting protein |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of STYX mRNA |
CTD |
PMID:17183730 |
|
NCBI chr15:18,565,214...18,595,797
Ensembl chr15:18,564,633...18,593,524
|
|
G |
Sufu |
SUFU negative regulator of hedgehog signaling |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of SUFU mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 1:245,257,725...245,355,576
Ensembl chr 1:245,257,768...245,355,577
|
|
G |
Sumo3 |
small ubiquitin-like modifier 3 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of SUMO3 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr20:11,010,140...11,020,850
Ensembl chr20:11,007,148...11,020,877 Ensembl chr20:11,007,148...11,020,877
|
|
G |
Syp |
synaptophysin |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of SYP mRNA |
CTD |
PMID:17183730 |
|
NCBI chr X:14,849,444...14,864,553
Ensembl chr X:14,849,444...14,864,745
|
|
G |
Syt6 |
synaptotagmin 6 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of SYT6 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 2:191,093,009...191,152,283
Ensembl chr 2:191,093,007...191,149,956
|
|
G |
Tacc2 |
transforming, acidic coiled-coil containing protein 2 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of TACC2 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 1:185,139,223...185,327,881
Ensembl chr 1:185,116,111...185,327,881
|
|
G |
Taf12 |
TATA-box binding protein associated factor 12 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of TAF12 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 5:144,472,816...144,490,299
Ensembl chr 5:144,472,841...144,488,849
|
|
G |
Tafa1 |
TAFA chemokine like family member 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of TAFA1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 4:128,738,028...129,244,223
Ensembl chr 4:128,739,313...129,243,777
|
|
G |
Taldo1 |
transaldolase 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of TALDO1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 1:196,493,634...196,503,965
Ensembl chr 1:196,493,589...196,503,974
|
|
G |
Tbc1d1 |
TBC1 domain family member 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of TBC1D1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr14:43,936,820...44,135,133
Ensembl chr14:43,935,636...44,136,499
|
|
G |
Tbcd |
tubulin folding cofactor D |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of TBCD mRNA |
CTD |
PMID:17183730 |
|
NCBI chr10:106,717,340...106,874,126
Ensembl chr10:106,717,367...106,874,122
|
|
G |
Tbrg1 |
transforming growth factor beta regulator 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of TBRG1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 8:37,355,274...37,362,933
Ensembl chr 8:37,354,658...37,362,930
|
|
G |
Tbx18 |
T-box transcription factor 18 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of TBX18 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 8:88,652,054...88,680,081
Ensembl chr 8:88,652,054...88,680,058
|
|
G |
Tcerg1 |
transcription elongation regulator 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of TCERG1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr18:34,505,708...34,566,470
Ensembl chr18:34,505,751...34,566,470
|
|
G |
Tcf12 |
transcription factor 12 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of TCF12 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 8:72,490,447...72,799,265
Ensembl chr 8:72,492,567...72,799,201
|
|
G |
Tec |
tec protein tyrosine kinase |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of TEC mRNA |
CTD |
PMID:17183730 |
|
NCBI chr14:35,352,551...35,461,585
Ensembl chr14:35,352,829...35,461,557
|
|
G |
Tent5a |
terminal nucleotidyltransferase 5A |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of TENT5A mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 8:86,222,294...86,229,045
Ensembl chr 8:86,225,357...86,229,045
|
|
G |
Tfcp2 |
transcription factor CP2 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of TFCP2 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 7:131,616,777...131,658,995
Ensembl chr 7:131,616,785...131,658,939
|
|
G |
Tfdp1 |
transcription factor Dp-1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of TFDP1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr16:76,162,040...76,200,871
Ensembl chr16:76,162,043...76,200,817
|
|
G |
Tff2 |
trefoil factor 2 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of TFF2 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr20:9,215,750...9,219,619
Ensembl chr20:9,215,761...9,219,619
|
|
G |
Tgif2 |
TGFB-induced factor homeobox 2 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of TGIF2 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 3:145,333,152...145,348,599
Ensembl chr 3:145,333,418...145,348,596 Ensembl chr17:145,333,418...145,348,596
|
|
G |
Thbd |
thrombomodulin |
multiple interactions |
EXP |
Hydralazine inhibits the reaction [Nitric Oxide deficiency results in decreased expression of THBD protein] |
CTD |
PMID:16778335 |
|
NCBI chr 3:135,863,366...135,867,018
Ensembl chr 3:135,862,835...135,867,193
|
|
G |
Them6 |
thioesterase superfamily member 6 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of THEM6 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 7:106,606,570...106,609,747
Ensembl chr 7:106,606,570...106,609,746
|
|
G |
Thrap3 |
thyroid hormone receptor associated protein 3 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of THRAP3 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 5:138,445,284...138,487,544
Ensembl chr 5:138,445,295...138,487,477
|
|
G |
Thy1 |
Thy-1 cell surface antigen |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of THY1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 8:44,389,495...44,394,688
Ensembl chr 8:44,389,513...44,394,659
|
|
G |
Timm13 |
translocase of inner mitochondrial membrane 13 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of TIMM13 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 7:8,809,069...8,810,172
Ensembl chr 7:8,809,058...8,809,910
|
|
G |
Timm50 |
translocase of inner mitochondrial membrane 50 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of TIMM50 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 1:83,574,872...83,582,748
Ensembl chr 1:83,556,757...83,582,793
|
|
G |
Timm8b |
translocase of inner mitochondrial membrane 8 homolog B |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of TIMM8B mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 8:50,954,350...50,955,730
Ensembl chr 8:50,954,342...50,955,729
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
decreases expression |
EXP |
hydralazine decreases expression of Timp1 protein in blood serum |
RGD |
PMID:33315911 |
RGD:407420266 |
NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664
|
|
G |
Timp2 |
TIMP metallopeptidase inhibitor 2 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of TIMP2 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr10:103,541,199...103,590,611
Ensembl chr10:103,531,505...103,590,611
|
|
G |
Tiprl |
TOR signaling pathway regulator |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of TIPRL mRNA |
CTD |
PMID:17183730 |
|
NCBI chr13:77,527,176...77,552,026
Ensembl chr13:77,527,176...77,552,074
|
|
G |
Tle5 |
TLE family member 5, transcriptional modulator |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of TLE5 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 7:8,143,357...8,150,295
Ensembl chr 7:8,143,357...8,150,113
|
|
G |
Tm7sf3 |
transmembrane 7 superfamily member 3 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of TM7SF3 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 4:179,518,127...179,550,154
Ensembl chr 4:179,518,130...179,550,154
|
|
G |
Tma7 |
translation machinery associated 7 homolog |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of TMA7 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 8:109,726,213...109,730,902
Ensembl chr 8:109,726,196...109,735,474
|
|
G |
Tmco1 |
transmembrane and coiled-coil domains 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of TMCO1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr13:79,460,229...79,483,557
Ensembl chr13:79,460,135...79,483,555
|
|
G |
Tmed3 |
transmembrane p24 trafficking protein 3 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of TMED3 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 8:90,241,516...90,249,429
Ensembl chr 8:90,241,516...90,249,346
|
|
G |
Tmem248 |
transmembrane protein 248 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of TMEM248 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr12:26,430,775...26,457,105
Ensembl chr12:26,432,953...26,457,105
|
|
G |
Tmem260 |
transmembrane protein 260 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of TMEM260 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr15:21,734,119...21,804,049
Ensembl chr15:21,734,151...21,806,801
|
|
G |
Tmem80 |
transmembrane protein 80 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of TMEM80 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 1:196,435,999...196,444,368
Ensembl chr 1:196,436,003...196,444,367 Ensembl chr 1:196,436,003...196,444,367
|
|
G |
Tmem9 |
transmembrane protein 9 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of TMEM9 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr13:47,458,486...47,475,832
Ensembl chr13:47,458,498...47,475,832
|
|
G |
Tmsb10 |
thymosin, beta 10 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of TMSB10 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 4:105,009,959...105,011,095
Ensembl chr 4:105,009,212...105,011,028
|
|
G |
Tnf |
tumor necrosis factor |
decreases secretion multiple interactions increases expression |
ISO EXP |
Hydralazine results in decreased secretion of TNF protein Vehicle Emissions inhibits the reaction [Hydralazine results in increased expression of TNF mRNA] |
CTD |
PMID:16612254 PMID:23415681 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfaip8 |
TNF alpha induced protein 8 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of TNFAIP8 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr18:43,183,854...43,299,512
Ensembl chr18:43,183,916...43,299,517
|
|
G |
Tomm20 |
translocase of outer mitochondrial membrane 20 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of TOMM20 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr19:54,925,197...54,935,188
Ensembl chr19:54,923,402...54,935,198
|
|
G |
Tomm7 |
translocase of outer mitochondrial membrane 7 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of TOMM7 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 4:11,305,122...11,311,963
Ensembl chr 4:11,305,110...11,311,962
|
|
G |
Topbp1 |
DNA topoisomerase II binding protein 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in decreased expression of TOPBP1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 8:103,887,805...103,931,662
Ensembl chr 8:103,887,865...103,931,674
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions increases activity |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of TP53 mRNA Hydralazine results in increased activity of TP53 protein |
CTD |
PMID:12082016 PMID:17183730 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Tpi1 |
triosephosphate isomerase 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of TPI1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 4:157,615,283...157,618,813
Ensembl chr 4:157,615,386...157,619,541
|
|
G |
Tpm2 |
tropomyosin 2 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of TPM2 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 5:57,770,919...57,780,278
Ensembl chr 5:57,770,864...57,779,992
|
|
G |
Tpsab1 |
tryptase alpha/beta 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of TPSAB1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr10:14,360,396...14,362,811
Ensembl chr10:14,360,396...14,362,811
|
|
G |
Tpte2 |
transmembrane phosphoinositide 3-phosphatase and tensin homolog 2 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of TPTE2 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr16:69,658,874...69,756,571
Ensembl chr16:69,658,875...69,752,949
|
|
G |
Traf2 |
Tnf receptor-associated factor 2 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of TRAF2 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 3:8,341,950...8,366,609
Ensembl chr 3:8,341,951...8,366,538
|
|
G |
Trappc4 |
trafficking protein particle complex subunit 4 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of TRAPPC4 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 8:44,729,458...44,733,285
Ensembl chr 8:44,725,331...44,733,491
|
|
G |
Trappc6a |
trafficking protein particle complex subunit 6A |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of TRAPPC6A mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 1:79,158,587...79,165,502
Ensembl chr 1:79,158,529...79,165,493
|
|
G |
Trib2 |
tribbles pseudokinase 2 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of TRIB2 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 6:38,545,971...38,570,349
Ensembl chr 6:38,545,975...38,569,370
|
|
G |
Trim46 |
tripartite motif-containing 46 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of TRIM46 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 2:174,641,494...174,654,237
Ensembl chr 2:174,641,496...174,654,141
|
|
G |
Trip10 |
thyroid hormone receptor interactor 10 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of TRIP10 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 9:2,133,085...2,147,795
Ensembl chr 9:2,133,671...2,147,799
|
|
G |
Trip6 |
thyroid hormone receptor interactor 6 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of TRIP6 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr12:19,386,212...19,390,619
Ensembl chr12:19,386,014...19,390,618
|
|
G |
Trpt1 |
tRNA phosphotransferase 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of TRPT1 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 1:204,186,295...204,191,294
Ensembl chr 1:204,186,295...204,191,294
|
|
G |
Tsen54 |
tRNA splicing endonuclease subunit 54 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of TSEN54 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr10:101,041,607...101,050,088
Ensembl chr10:101,042,503...101,050,087
|
|
G |
Tspan10 |
tetraspanin 10 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of TSPAN10 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr10:105,715,803...105,721,503
Ensembl chr10:105,715,961...105,719,813
|
|
G |
Tspan18 |
tetraspanin 18 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of TSPAN18 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 3:79,160,060...79,299,907
Ensembl chr 3:79,161,662...79,299,852
|
|
G |
Tspo |
translocator protein |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of TSPO mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 7:114,720,188...114,730,450
Ensembl chr 7:114,720,188...114,730,450
|
|
G |
Tst |
thiosulfate sulfurtransferase |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of TST mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 7:109,948,061...109,955,378
Ensembl chr 7:109,948,062...109,957,216
|
|
G |
Tubb6 |
tubulin, beta 6 class V |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of TUBB6 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr18:60,943,394...60,953,031
Ensembl chr18:60,943,375...60,954,418
|
|
G |
Tyw3 |
tRNA-yW synthesizing protein 3 homolog |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of TYW3 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 2:243,529,912...243,552,043
Ensembl chr 2:243,529,946...243,552,039
|
|
G |
Uba52 |
ubiquitin A-52 residue ribosomal protein fusion product 1 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of UBA52 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr16:18,918,614...18,920,807
Ensembl chr16:18,900,616...18,920,807
|
|
G |
Ube2l6 |
ubiquitin-conjugating enzyme E2L 6 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in increased expression of UBE2L6 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 3:69,873,025...69,888,042
Ensembl chr 3:69,873,424...69,888,048
|
|
G |
Ubox5 |
U-box domain containing 5 |
multiple interactions |
ISO |
[Hydralazine co-treated with Valproic Acid] results in decreased expression of UBOX5 mRNA |
CTD |
PMID:17183730 |
|
NCBI chr 3:117,806,212...117,847,711
Ensembl chr 3:117,807,092...117,847,722
|
| |